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Cancer is a common problem in dogs and although all breeds of dog and crossbred dogs may be aﬀected, it is notable that some
breeds of pedigree dogs appear to be at increased risk of certain types of cancer suggesting underlying genetic predisposition to
cancer susceptibility. Although the aetiology of most cancers is likely to be multifactorial, the limited genetic diversity seen in
purebred dogs facilitates genetic linkage or association studies on relatively small populations as compared to humans, and by
using newly developed resources, genome-wide association studies in dog breeds are proving to be a powerful tool for unravelling
complex disorders. is paper will review the literature on canine breed susceptibility to histiocytic sarcoma, osteosarcoma,
haemangiosarcoma,mast cell tumours, lymphoma,melanoma, andmammary tumours including the recent advances in knowledge
through molecular genetic, cytogenetic, and genome wide association studies.
1. Introduction
Cancer is an important disease in dogs and represents one of
the major causes of canine death accounting for 27% of all
deaths in purebred dogs in the UK in a recent mortality study
[1]. is is slightly higher than what previously reported in
a Danish Kennel club study (14.5% by Proschowesky et al.)
and an earlier UK study (15.7% by Michell) but similar to a
postmortem series of 2000 dogs, in which 23% of all dogs and
45% of dogs over 10 years of age died of cancer [2]. In the
absence of reliable historical tumour registries, it is diﬃcult
to know whether the prevalence of cancer in dogs is actually
increasing; however a number of factors may contribute to
an increase in the diagnosis of cancer in dogs; as a result of
improvements in health and welfare animals are living longer
and cancer is generally a disease of older age [3]. Advances
in veterinary medicine, particularly diagnostics and higher
expectations of the pet owning public, are likely to result in
an increased rate of diagnosis.
As is the case in the human population, many diﬀerent
types of naturally occurring cancer may aﬀect dogs and
caninemalignancies have been established as strong compar-
ative models for the human disease due to their spontaneous
development and frequency; dogs live in our environment
and eat similar food and are thus exposed to similar risk
factors, so the aetiology and pathogenesis of canine tumours
is likely to be similar to that of human tumours [4–8]. A
general comparison of the incidence of canine cancer with
that of human cancer highlights some striking similarities
and diﬀerences [9]. Breast cancer is the most common
malignancy in women and the mammary gland is a common
site for tumour development in bitches, although the risk is
reduced in bitches spayed at a young age [10], demonstrating
the importance of endogenous hormones in the development
of this disease. In contrast, carcinomas of the prostate, a
very common condition in men and also associated with
hormonal stimulation, is relatively uncommon in dogs and
occurs more frequently in neutered dogs [11]. Carcinomas of
the lung and large bowel, the most common human tumours
excluding breast and prostate, do not feature highly in the
canine population, whereas so tissue sarcomas, which are
rare in humans, are relatively common in dogs.
However, whilst general trends for the occurrence of
canine cancers are well established, accurate �gures for
the frequency of diﬀerent types of tumours in the canine
population are limited. One study of insured dogs from the
United Kingdom showed the skin and so tissues to be the
most common sites for tumour-related claims (both benign
and malignant) with a standardised incidence rate of 1437
per 100,000 dogs/year, followed by mammary, urogenital,
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F 1: Incidence of speci�c types of canine neoplasia. From [12]
(Pink bars denote malignant tumours, blue benign lesions).
lymphoid, endocrine, alimentary, and oropharyngeal sites.
Canine cutaneous histiocytoma was the most common
tumour type overall with a standardised incidence rate of
337 per 100,000 dog/year, followed by lipoma, adenoma, so
tissue sarcoma, mast cell tumour, and lymphoma (Figure
1, [12]). Other epidemiological studies, based on hospital
populations or on surveys of intakes into pathology labora-
tories, are largely supportive of these estimates for the canine
population as a whole [13–17], as are recent �gures from a
number of European Tumour Registries [18–20].
It is well recognised that diﬀerences exist between breeds
of dog and their risk of developing certain types of cancer
but there are few large scale epidemiological studies on the
incidence of diﬀerent types of cancer in the canine population
which document the variation between breeds. e breeds
with the highest proportionalmortality for cancer in theKen-
nel Club/BSAVA study included the following, in descending
order: Irish water spaniel, �at-coated retriever, Hungarian
wirehaired vizsla, Bernese mountain dog, rottweiler, Italian
spinone, leonberger, Staﬀordshire bull terrier, Welsh terrier,
and giant Schnauzer ([1], Table 1). In a study of rates and
causes of death in insured dogs in Sweden, Bonnett et al.
[16] found that the Bernese mountain dog, Irish wolound,
�at-coated retriever, boxer, and Saint Bernard were the �ve
breeds of dog with the highest mortality from tumour-related
death.eBernese, Irish wolound, and leonberger were the
top three in a subsequent examination of the same data base
[21]. Bernese mountain dogs, �at-coated retrievers, golden
retriever, and rottweilers were in the top 5 breeds with over
20% of deaths due to cancer in Denmark [22]. An owner-
based questionnaire conducted in the UK segregated breeds
into “overrepresented,” “average” and “underrepresented”
with respect to dying of cancer and showed the same trends
(Table 2) [23].ese population-based studies provide useful
indicators of breeds at risk of cancer, but should not be
regarded as completely de�nitive because the outcome oen
depends on the breed prevalence within the population at
risk, which may explain the diﬀerences found in studies
from diﬀerent countries. e existence of other inherited
diseases or breed-associated problems is amajor confounding
factor: for example the reason the bulldog has an apparent
low risk of cancer in Table 1 may be due to its short life-
expectancy due to other health issues that aﬀect the breed
[24]. Other limitations of such studies include owner compli-
ance, bias through nonrandom sampling of the pedigree dog
population, and accuracy of owner-reported cause of death.
Furthermore a small number of dogs can seriously bias the
results for numerically small breeds, as demonstrated by the
red and white setter in Table 2 and probably the Hungarian
wireheriad vizsla, and Welsh terrier in Table 1. However, the
fact that all these studies consistently show similar overall
breed-related predispositions to development of cancer has
important implications in understanding the aetiology of
cancer as it infers a genetic and heritable component.
e dog has a unique population structure with each
breed arising from a limited number of founders. e dog
is believed to have evolved from grey wolves possibly from
Europe or the Middle East although interbreeding with local
wolf populations clearly occurred elsewhere in the early
history of dog lineages [25–27]. Although the wolf dog
became domesticated 20–30,000 years ago, and dog types
were gradually established for guarding, herding, and hunting
purposes, it is only in the past 200 years or so that selective
breeding practices have divided the dog population into over
300 discrete breeds worldwide. e English Kennel Club
was established in the Victorian era to meet the demands
of the dog breeding Populus, to regulate the registration of
dog breeds, and to establish breed standards. Kennel clubs
in Europe and America still impose strict standards on
registration of pedigree dogs requiring that the ancestors of
each dog must be registered as well. is combined with the
frequent use of popular sires and inbreeding practices means
that each breed is a closed, isolated population with virtually
no gene �ow between breeds [28]. Over the past 200 years
this practice has resulted in reduced genetic diversity within
breeds and greater genetic divergence between breeds. e
average nucleotide heterozygosity when considered across
dog breeds is comparable to the human population [29],
but the level of genetic diversity within any single breed is
considerably less than the species as a whole [25] indeed it
has been estimated that whilst domestication of wild canid
populations resulted in a 5% loss of nucleotide diversity,
breed formation caused a 35% loss [30]. In many breeds
the eﬀective population size is very small even in normal
times but in some breeds, for example, the Bernese mountain
dog and the leonberger, genetic variation has been further
reduced by serious population declines during war or hard
economic times [31]. Mutations in a small number of genes
of large eﬀect are responsible for many breed characteristics;
such selective breeding for exaggerated traits further reduces
genetic diversity, and perhaps risks selection of mutations
that predispose to disease [25, 32, 33]. Over 350 inherited
disorders have been described in purebred dogs many of
ISRN Veterinary Science 3
T 1: Proportional cancer-related mortality by breed. Based on data from [1], cancer accounted for 27% of deaths (4282 of 15,881).
Breed All deaths Cancer-related death Median age at deathN % 95% CI
Irish water spaniel 95 53 55.8 45.8–65.8 9.33
Flat-coated retriever 610 331 50.3 50.3–58.2 9.83
Hungarian wirehaired vizsla 15 7 46.7 21.4–71.9 9.83
Bernese mountain dog 394 180 45.7 40.8–50.6 8.0
Rottweiler 137 62 45.3 36.9–53.6 8.92
Italian spinone 47 21 44.7 30.5–58.9 9.0
Leonberger 47 21 44.7 30.5–58.9 7.08
Staﬀordshire bull terrier 117 52 44.4 35.4–53.4 12.75
Welsh terrier 23 10 43.5 23.3–63.7 12.67
Giant schnauzer 39 16 41 25.6–56.6 10.0
Airedale terrier 81 32 39.5 28.9–50.2 10.75
Golden retriever 927 360 38.8 35.7–42.0 12.25
Boxer 130 50 38.5 30.1–46.8 10.25
Briard 71 27 38.0 26.7–49.3 11.17
French bulldog 71 27 38.0 26.7–49.3 9.0
Bullmastiﬀ 96 36 37.5 27.8–47.2 7.46
Alaskan Malamute 14 5 35.7 10.6–60.8 10.71
Saluki/gazelle hound 132 47 35.6 27.4–43.8 12.0
Nova Scotia duck tolling retriever 9 3 33.3 2.5–64.1 8.0
Basset griﬀon vendeen 76 25 32.9 22.3–43.5 12.04
Beagle 241 79 32.8 26.9–38.7 12.67
English setter 384 126 32.8 28.1–37.5 11.58
Norwegian elkhound 71 23 32.4 21.5–43.3 13.17
Siberian Husky 129 41 31.8 23.7–39.8 12.58
Keeshond 104 33 31.7 22.8–40.7 12.21
Tibetan terrier 95 30 31.6 22.2–40.9 12.17
Basset hound 142 44 31.0 23.4–38.6 11.29
Labrador retriever 574 179 31.2 27.4–35.0 12.25
Afghan hound 143 44 30.8 23.2–38.3 11.92
Rhodesian ridgeback 183 56 30.6 23.9–37.3 11.0
Irish red and white setter 179 54 30.2 23.4–36.9 11.42
Standard poodle 118 35 29.7 21.4–37.9 12.0
German shorthaired pointer 159 47 29.6 22.5–36.7 12.0
Cocker spaniel/English cocker 289 85 29.4 24.2–34.7 11.17
Field spaniel 68 20 29.4 18.6–40.2 11.63
Welsh corgi Pembroke 116 33 28.4 20.2–36.7 12.21
Welsh corgi cardigan 53 15 28.3 16.2–40.4 12.17
Gordon setter 157 46 29.3 22.2–36.4 11.08
Irish setter 451 123 27.3 23.3–31.4 12.0
Newfoundland 269 73 27.1 21.8–32.5 9.67
Welsh springer spaniel 157 42 26.8 19.8–33.7 12.58
English springer spaniel 90 24 26.7 17.5–35.8 12.0
Lancashire heeler 30 8 26.7 10.8–42.5 11.75
Samoyed 223 59 26.5 20.7–32.2 12.5
Doberman 100 26 26 17.4–34.6 10.5
So coated wheaten terrier 111 29 26.1 18.0–34.3 12.5
Large Munsterlander 69 17 24.6 14.5–34.8 11.33
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T 1: Continued.
Breed All deaths Cancer-related death Median age at deathN % 95% CI
German wirehaired pointer 41 10 24.4 11.2–37.5 10.0
Weimaraner 242 58 24.0 18.6–29.3 11.13
Border collie 106 25 23.6 15.5–31.7 12.25
Tibetan spaniel 125 29 23.2 15.8–30.6 14.42
Belgian shepherd 113 26 23.0 15.2–30.8 12.5
Bull terrier 209 48 23.0 17.3–28.7 10.0
Dandy Dinmont terrier 62 14 22.6 12.2–33.0 12.17
Shetland sheepdog 365 81 22.3 18.0–26.5 12.5
Manchester terrier 32 7 21.9 7.6–36.2 12.83
Norwich terrier 56 12 21.4 10.7–32.2 13.38
Miniature schnauzer 214 46 21.5 16.0–27.0 12.08
Pointer 145 30 20.7 14.1–27.3 12.42
Finnish spitz 42 9 21.4 9.0–33.8 11.13
Bearded collie 278 54 19.4 14.8–24.1 13.5
Cairn terrier 124 24 19.4 12.4–26.3 14.0
Dalmatian 199 38 19.1 13.6–24.6 12.67
Border terrier 177 34 19.2 13.4–25.0 14.0
Sussex spaniel 42 8 19.0 7.2–30.9 11.13
Deerhound 287 54 18.8 14.3–23.3 8.6
Bulldog/British bulldog 180 33 18.3 12.7–24.0 6.29
Lhasa Apso 84 15 17.9 9.7–26.0 14.33
Dachshund (all) 245 41 16.7 12.1–21.4 10.75
German spitz/klein or mittel 43 7 16.3 5.2–27.3 11.33
Shih tzu 83 12 14.5 6.9–22.0 13.17
Other breeds (n = 93) 4524 806 17.8
Total 15,881 4282 27.0
which are equivalent to human diseases [34, 35]. e limited
genetic diversity seen in purebred dogs, facilitates genetic
linkage or association studies on relatively small popula-
tions as compared to humans [36, 37] and by using newly
developed resources, genome wide association studies in dog
breeds are proving to be a powerful tool for unravelling
complex disorders [38]. Although most forms of cancer are
likely multifactorial in aetiology, the fact that diﬀerent breeds
of dog are predisposed to developing certain types of cancer
(and conversely some breeds are at lesser risk) oﬀers a unique
opportunity to study and understand the geneticmechanisms
underpinning cancer susceptibility [39, 40].
e purpose of this article is to review the current litera-
ture on predispositions to cancer in pedigree dogs, including
the recent advances in knowledge throughmolecular genetic,
cytogenetic, and genome wide association studies and to
consider how the application of this new knowledge will
informour approach to the diagnosis, treatment, and possibly
prevention of cancer in the future.
Table 1, taken from the results of a health survey of
purebred dogs in the UK [1], lists the proportional mortality
for diﬀerent breeds. e mean mortality rate to cancer for
all breeds was 27%, thus those breeds recording greater than
30% deaths from cancer might be considered to be at greater
risk or predisposed and those less than 25% cancer deaths,
at reduced risk, although that is not to say that these latter
breeds do not suﬀer particular types of cancer; for example,
the Belgian shepherd has been documented to be at higher
risk of gastric carcinoma [41] and the Scottish deerhound
has been shown to have a heritable risk of osteosarcoma
[42]. Considering the genetic structure of the purebred
dog, phylogenetic analysis has shown separation of several
breeds with ancient origin from a large group of breeds
with presumed European origins. e former include the
spitz type breeds: Shar-Pei, Shiba Inu, Chow Chow, Akita,
Siberian Husky, and Alaskan Malamute. Further studies
to characterise genetic variation within and among breeds
established at least four distinct breed groupings: a subset
of breeds with ancient Asian and African origins (as above
but also including Basenji fromAfrica, Saluki, Afghan hound
from the Middle East, and tibetan Terrier, Lhasa Apso from
china), a group of Mastiﬀ-like breeds, a group re�ecting
shared ancestral herding behaviour, and a group of hunting-
type dogs (Figure 2) [43]. Most recently a neighbor-joining
tree of domestic dogs showing the relationship among the
various dog breeds has been constructed by genotyping 10
to 12 dogs for each of 80 breeds (Figure 3) [26]. Breeds that
share either common behaviors or morphologic traits are
grouped together on the basis of DNA analysis, indicating
that they probably share common ancestors. In this context
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T 2: Adapted from [23] Table 5, percentage of deaths due to cancer suﬀered by dogs of diﬀerent breeds compared with the percentage of
the breed in the survey population.
Breed % chance of dyingof cancer
% in survey
population Ratio
Tumour types for which breed has
been reported to be at risk
Overrepresented
Irish wolound 0.89 0.31 2.9 Osteosarcoma
Rottweiler 7.35 3.53 2.1 Osteosarcoma, histiocytic sarcoma,lymphoma
Afghan hound 0.67 0.38 1.8 Osteosarcoma
Standard poodle 1.34 0.8 1.7 SCC digit
Weimaraner 1.34 0.8 1.7 Mast cell tumour
Irish red and white setter 0.90 0.7 1.3
Staﬀordshire bull terrier 1.78 1.4 1.3 Mast cell tumour
Boxer 4.45 3.35 1.3 Mast cell tumour, glioma
Cairn terrier 1.34 1.12 1.2
Old English sheepdog 2.00 1.61 1.2
Golden retriever 8.91 7.16 1.2
Mast cell tumour, lymphoma, oral
melanoma, �brosarcoma, histiocytic
tumours
Flat-coated retriever 0.67 0.56 1.2 Histiocytic sarcoma
Average
Dobermann 2.67 2.48 1.1
English springer spaniel 3.79 3.63 1.0
Labrador retriever 11.58 11.45 1.0 Mast cell tumour
Great Dane 1.34 1.54 0.9 Osteosarcoma
Underrepresented
Border collie 1.56 2.02 0.8
Cocker spaniel 3.12 3.73 0.8 Anal gland adenocarcinoma
Crossbred 13.36 16.58 0.8
German shepherd 8.46 10.02 0.8 Haemangiosarcoma
West Highland white terrier 2.00 2.79 0.7
Shetland sheepdog 0.89 1.40 0.6
Yorkshire terrier 1.34 2.2 0.6
Jack Russell 1.34 2.62 0.5
Rough Collie 0.67 1.78 0.4 Gastric carcinoma
Bulldog 0.22 0.59 0.4 Mast cell tumour, glioma
Welsh springer spaniel 0.22 0.52 0.4
Airedale 0.22 0.63 0.3
Irish setter 0.22 0.7 0.3
Dachshund 0.22 1.43 0.2
Cavalier King Charles spaniel 0.45 2.06 0.2
Beagle 0 0.56 0 Mammary tumours
it is notable how some breed groupings “rank” in Table
1, with the Mastiﬀ-type breeds dominating the top of the
table and most of the ancient spitz type breeds below the
mean. However, it is not possible to know whether this
observation re�ects genetic predisposition to cancer or body
size or perhaps that the two are interrelated. Body size
has previously been shown to correlate with longevity, with
smaller breeds having a longer life expectancy [1, 23]. Of
the breeds listed as over-represented in Tables 1 and 2,
some have been associated with speci�c types of tumour, for
example, Bernese mountain dog—systemic and malignant
histiocytosis, Irish wolound—osteosarcoma, and others
with a higher risk of more than one tumour type for
example Boxer—mast cell tumour and brain tumour, Golden
6 ISRN Veterinary Science
Domestication
European breeds
Breed formation
Herding Hunting
Wolf ancestor
Modern
wolves
Wild and
village dogs
Ancient spitz
breeds
Mastiff-like
F 2: A simpli�ed schematic summary of dog evolution: depicting the two evolutionary �bottle necks�: domestication and breed
formation. It has been estimated that domestication of wild wolf-canine populations resulted in a 5% loss of nucleotide diversity, breed
formation has caused a 35% loss [30].
retriever—mast cell tumour, lymphoma, hemangiosarcoma.
is observation also has important genetic implications,
suggesting that some breeds may be like the rare human Li-
Fraumeni families where a germ line mutation in a tumour
suppressor gene (TP53) results in a hereditary predisposition
to several types of cancer [44] or they may resemble the
situation in families with mutations in BRCA1 where the risk
of developing breast and ovarian cancer is greater in relatives
of aﬀected people, rather than the cancer being transmitted
as an autosomal dominant condition [45, 46]. In contrast
other breeds aﬀected by a speci�c type of tumour may have a
more speci�c genetic abnormality leading to that particular
type of tumour. For example, renal cystadenocarcinoma
and nodular dermato�brosis (RCND) is a rare inherited
cancer syndrome in German shepherd dogs. Aﬀected dogs
develop bilateral multifocal tumours in the kidneys and
multiple dense collagenous skin nodules [47]. In the dog the
disease gene was mapped to a region on canine chromosome
5q12, corresponding to a gene encoding tumour-suppressor
protein folliculin [48]. It was subsequently shown that the
same gene ismutated in Birt-Hogg-Dube syndrome, a similar
disease in humans [49].
For the purpose of this paper, breed associations will be
considered by tumour type rather than by breed.
2. Histiocytic Sarcoma
Histiocytic sarcoma is the current term used to describe
a spectrum of poorly diﬀerentiated, pleomorphic tumours
shown to have an immunophenotype consistent with a
myeloid dendritic antigen presenting cell origin: CD1+,
CD4−, CD11c+, CD11d−, MHC II+, ICAM−1+, andy−1±
[50]. As many of these reagents cannot be used on formalin
�xed para�n embedded sections, vimentin, MHC II, and the
cell surface marker CD18 have become the standard panel
for identi�cation of histiocytic sarcoma [51, 52]. Localised
histiocytic sarcoma describes those lesions which present as
solitary masses, previously referred to as malignant �brous
histiocytoma [53–56], and disseminated histiocytic sarcoma,
those that present withmultifocal lesions, previously referred
to as malignant histiocytosis [50]. Whilst histiocytic sarcoma
is an uncommon tumour in the dog population as a whole,
certain pedigree breeds appear predisposed to this disease,
notably the Bernese mountain dog where the disseminated
form of histiocytic sarcoma accounts for up to 25% of deaths
in the breed [57] and the �at-coated retriever where the
localised form is more common and accounts for approxi-
mately 25% of all tumours in the breed, and up to 50% of
all malignancies [58, 59]. Disseminated histiocytic sarcoma
in the Bernese typically presents with vague clinical signs
including lethargy, anorexia, and weight loss. Investigations
revealmultifocal disease primarily aﬀecting the lungs, spleen,
liver, bone marrow, and lymph nodes. Haematological
abnormalities including anemia and thrombocytopenia are
common [60–63]. e disease is rapidly progressive and
fatal; many dogs are euthanized upon diagnosis; survival
time from diagnosis has been reported to be 49 days [64].
In �at-coated retrievers localised lesions most commonly
develop in the deep musculature of the limbs or in peri-
articular sites; the elbow is the most common site [65].
Even these localised lesions are highly malignant with rapid
dissemination to lymph nodes preceding haematogenous
spread to parenchymal organs and the skin in over 70% of
cases [66]. us both the localised and disseminated forms
of histiocytic sarcoma are highly malignant conditions that
are largely refractory to conventional treatments and carry
a very poor prognosis. Treatment with Lomustine (CCNU)
has been reported to result in some short term responses
[56, 66–68]. e archetype of Bernese mountain dogs, being
aﬀected by the disseminated form of the disease, and �at-
coated retrievers by the localised form, is not entirely accurate
as up to 30% of histiocytic sarcomas in �at-coated retrievers
are actually visceral, arising most commonly in the spleen
with other visceral sites including liver, lung, mediastinum,
and lymph nodes also aﬀected [65]. Included in the visceral
form aﬀecting this breed is the hemophagocytic variant
of histiocytic sarcoma, which arises from splenic or bone
marrow derived macrophages and expresses CD11d [69, 70].
Furthermore localised periarticular histiocytic sarcoma is
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(b)
F 3: Summary of the neighbour-joining tree of domestic dogs [26] showing relationships between diﬀerent breeds of dog on the basis
of DNA analyses. Breeds that share either common behaviours or morphologic traits are grouped together on the basis of DNA analysis,
indicating that they probably share common ancestors. e colours indicate breeds that probably share common founders.
also recognised in the BMD, where it is possibly predisposed
by joint disease [71]. Histiocytic sarcoma is not exclusive
to the Bernese and �at-coated retriever� other breeds of
dog where histiocytic sarcoma has been reported with some
frequency include rottweilers and golden retrievers [50, 72–
75].
e striking high incidence of histiocytic sarcoma in
these breeds of dog suggests a heritable predisposition. A
recent study of Danish Bernese mountain dogs described 13
dogs diagnosed with malignant histiocytosis, of which 11
were genealogically related [76]. In 1995 Padgett analysed
the inheritance of “histiocytosis” in 127 aﬀected Bernese
mountain dogs and suggested a polygenic mode of inher-
itance and a calculated heritability of 0.298 [57]. More
recently a pedigree of 327 Bernese mountain dogs (144
males, 183 females) was developed from 800 French and
European dogs. A total of 121 dogs had a clinical diagnosis
of histiocytic sarcoma. Detailed analysis of this pedigree
showed that the segregation of the disease observed in these
families could not be explained by a fully recessive model
and that an oligogenic model was likely to be a better
description of the genetic model underlying the disease
[64]. Histiocytic sarcoma has recently been investigated by
molecular cytogenetic pro�ling [77] and genome wide asso-
ciation studies [78]. Using genome wide array comparative
genomic hybridization, supplemented with �uorescence in
situ hybridization and loss of heterozygosity analysis, copy
number aberrations (CNAs) were assessed in 146 histiocytic
sarcomas, 101 from Bernese mountain dogs (68 from USA
and 33 from France) and 45 from �at-coated retrievers (all
from USA) [77]. Numerous CNAs were found, both gains
and losses, throughout the genome.irty-one regions of the
canine genome presented with recurrent CNAs of which 6
were highly recurrent, all of which were deletions located
on dog chromosomes 2, 11, 16, 22, and 31. Almost all
these recurrent CNAs were shared between the two breeds,
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suggesting that they are more associated with the cancer
phenotype than with breed and a subset suggested involve-
ment of known cancer-associated genes including deletions
of the tumour suppressor genesCDKN2A/B, RB1, and PTEN.
A small number of abberations were unique to each breed,
and the authors speculated that these may contribute to the
major diﬀerences in tumour location evident in the two
breeds [77]. Interestingly dysregulation of CDKN2 has also
been associated with susceptibility to histiocytic sarcoma in
Bernese mountain dogs by genome wide association study
(GWAS) [78]. DNA was isolated from 474 blood samples
from Bernese mountain dogs, 242 cases and 232 controls,
114 cases and 120 controls from North America and 128
cases and 112 controls from Europe. Both independent and
combined GWAS were used to identify cancer-associated
loci, �ne mapping and sequencing narrowed the primary
locus to a single region. Both populations shared the same
primary locus which featured a single haplotype spanning
MTAP and part of CDKN2A which was present on at least
one chromosome in 96% of aﬀected dogs, with 65% of
cases being homozygous [78]. is haplotype is within a
region homologous to human chromosome 9p21 which is an
important tumour suppressor locus and is implicated inmany
human cancers [79, 80]. It is likely that the MTAP-CDKN2
locus is associated with more than one tumour type; Bernese
mountain dogs are also susceptible to lymphoma, mast cell
tumours, and osteosarcoma which seem to show familial
clustering. However, the presence of the risk haplotype
among control dogs could be due to the fact that the risk
associated with this locus is modest and that at least some of
the control dogs lack additional risk alleles at other loci. Aer
all, it is likely that more than a single locus will be involved in
the predisposition [64, 78].
To date there are no published data on whether this
haplotype or tumour suppressor locus is important in his-
tiocytic sarcoma in other dog breeds especially rottweilers
or golden retrievers. However, there is some evidence that it
may be important in other canine sarcomas. Disruption of
chromosome 11 involving the loss of the CDKN2b-CDKN2a
tumour suppressor gene cluster region has been reported
in two �brosarcomas in Labrador retrievers [81]. e same
study sequenced exon 1 of CDKN2B using DNA from blood
of 141 dogs of 18 diﬀerent breeds and showed widespread
polymorphism of this �rst exon. Seven alleles were recorded
and sixteen of the eighteen breeds showed heterozygosity.
Further investigations into the role of this tumour suppressor
region in other canine so tissue sarcomas may yield some
interesting �ndings that may start to explain the relatively
high incidence of so tissue sarcomas in dogs in comparison
to humans, where such tumours are rare.
3. Osteosarcoma
Osteosarcoma of the long bones is the most common malig-
nant tumour of bone in dogs accounting for 85 −90% of
primary bone tumours and almost exclusively aﬀects the
large and giant breeds such as rottweiler, great Dane, Irish
wolound, greyhound, Saint Bernard [82]. e aetiology of
osteosarcoma is probably multifactorial; the predilection for
the tumour to develop at metaphyseal region of long bones,
especially the distal radius and proximal humerus, correlates
with weight bearing, and rapid bone growth during early
development along with bone stress due to weight bearing
(possibly resulting in microfractures) has been implicated
in the aetiology of these tumours [83]. Increasing weight
and height appear to be important predictive factors for
the disease in the dog [84]. Growth hormone has been
shown to be present in canine osteosarcoma samples [85]
and studies evaluating the role of insulin-like growth factor-
1 (IGF-1) and its receptor IGF-1R and hepatocyte growth
factor (HGF) and its receptor c-Met in osteosarcoma cell lines
and tissues have shown that these factors may contribute to
the malignant phenotype [86, 87]. Sex hormones may also
contribute to osteosarcoma riskwith intactmales and females
being reported to be at increased risk [84]. However in the
rottweiler neutering before 1 year of age appeared to increase
risk of bone sarcoma in bothmale and female dogs [88]. As is
the case inmany human and canine cancers, alterations in the
function of the tumour suppressor genes RB and TP53 have
been implicated in the pathogenesis of canine osteosarcoma
[89, 90]. e fact that speci�c breeds appear predisposed
suggests that more speci�c genetic factors may be implicated
in the aetiology of canine osteosarcoma. Breeds reported to
be at increased risk of developing osteosarcoma include the
doberman, German shepherd, golden retriever, great Dane,
Irish setter, rottweiler and Saint Bernard [88, 91, 92], large
sight-hounds such as Irish wolound, Scottish deerhound
and Borzoi [84], greyhound, rottweiler and great Dane [83]
and Irish wolound, Saint Bernard, and Leonberger [93].
It may be argued that these predispositions may be related
to size rather than breed, and this is supported by the
fact that greyhounds and whippets consistently clustered
together in an analysis of molecular variance inmicrosatellite
loci [26, 43], yet whilst appendicular osteosarcoma aﬀects
greyhounds [82], the disease is rare in whippets, or indeed
in dogs under 25 kg body weight [84, 94]. Interestingly IGF1
and its associated regions are a major contributing locus
in size diversity in dogs, accounting for about 50% of the
genetic variation in size [95]. Osteosarcoma is particularly
prevalent in retired racing Greyhounds, possibly implicating
stress or trauma in the aetiology of the disease in this
breed [83, 96]. A familial incidence has been observed in
Saint Bernards [91] and more recently a study modelling
the transmission of osteosarcoma in a population of over
1000 Scottish deerhounds estimated heritability at 0.69 and
modelling suggested that a major gene with dominant eﬀect
would explain the pattern of transmission [42].
It is well documented that canine osteosarcoma is a good
clinical model for the human disease [97–99] and there is a
growing body of evidence to show that canine and human
osteosarcoma have a similar molecular pathogenesis [100,
101]. Gene expression pro�ling of canine osteosarcoma has
revealed genes associated with progression, survival, and
metastasis that are relevant to human osteosarcoma [100,
102–105]. As is the case in human osteosarcoma, the canine
disease is characterised by an extremely complex karyotype
indicating extensive genomic instability. Using two breeds of
dog with diﬀerent relative risk of osteosarcoma—rottweiler
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(12.5% incidence rate) and golden retriever (5% incident
rate)—a recent study has shown that the individual genetic
background, as de�ned by breed, in�uences the tumour
karyotype in osteosarcoma [106]. Eleven loci (from 8 dif-
ferent chromosomes) showed a signi�cant diﬀerence in
the distribution of DNA copy number imbalances between
tumours from golden retrievers compared with those from
rottweilers; the most signi�cant of these was the deletion of
theWT1 gene which occurred in 48% of the rottweiler cases
(14/29) but which was not observed in any of the 9 golden
retrievers. Genomic loss of TP53 and CDKN2A suppressor
genes were also restricted to rottweilers (7/29 (24%) and
5.29 (17%), resp.). Overall 15/29 rottweilers in this study
showed genomic deletion of at least one of the WT1, TP53,
CDKN2A, PTEN, or RB1 tumour suppressor genes. ese
breed-associated imbalancesmay contribute to or result from
heritable risk factors. A larger study which pro�led 123 cases
of canine osteosarcoma by 1 Mb aCGH also demonstrated
a high occurrence of genetic imbalances similar to human
osteosarcoma and identi�ed several new candidate genes in
regions of the canine genome that had highly recurrent copy
number abnormalities [101]. Although this dog population
was represented by 4 main breeds, rottweiler (𝑛𝑛 𝑛 𝑛𝑛),
greyhound (𝑛𝑛 𝑛 𝑛𝑛), great Pyrenees (𝑛𝑛 𝑛 𝑛𝑛), and
golden retriever (𝑛𝑛 𝑛 𝑛𝑛), no signi�cant diﬀerences were
found between aCGHde�ned regional abberations and breed
groups. It is likely that larger cohorts with less variation in
tumour histology will be needed to provide the power to
detect signi�cance.
4. Hemangiosarcoma
Hemangiosarcoma is a highlymalignant tumour arising from
blood vessels, probably less common than some of the other
mesenchymalmalignancies, for example, �brosarcoma; it has
been estimated to represent 7% of canine malignant tumours
[5] and accounted for 24/100,000 dogs/year in one study
[12], which is still considerably higher than angiosarcoma
in humans [107]. e most common primary sites for
hemangiosarcoma in dogs are visceral organs, notably the
spleen and liver; itmay also arise in the right atrial appendage.
A dermal form of haemangiosarcoma is also seen in dogs,
which has a predilection for light haired or nonpigmented
skin, particularly on the ventral abdomen and UV light has
been implicated in the aetiology of this form of the disease
[108]. Visceral hemangiosarcoma has a predilection for cer-
tain breeds; the German shepherd dog has been reported to
have an increased risk with an odds ratio of 4.7 (95% CI
2.7–7.8) compared to other purebred dogs [109], but boxers
and golden retrievers have also been identi�ed as being at
increased risk [110, 111]. More recently hemangiosarcoma
appears to have become a signi�cant problem in golden
retrievers in North America with an estimated life-time risk
of 1 in 5 reported by the Golden Retriever Club of America
[112, 113].
A small number of studies have examined the molecular
genetic aspects of canine hemangiosarcoma with respect to
growth regulation genes; mutations in the tumour suppressor
gene TP53 have been reported [114, 115] and a further
study suggested that alteration of the p16-cyclin D1-Rb
pathway may be associated with the pathogenesis of canine
hemangiosarcoma. In this study only 18% of samples showed
alterations in both TP53 and p16 [116]. e Rb (p16)
pathway is also commonly deregulated in human cancers
[117]. As a naturally occurring tumour of endothelial cells,
the role of vascular endothelial growth factor (VEGF) in
the pathogenesis and progression of hemangiosarcoma has
been examined. VEGF has potent angiogenic, mitogenic,
and vascular permeability enhancing properties and plays
a major role in tumour growth in human cancers where
plasma concentrations of VEGF have been shown to correlate
with tumour burden and prognosis [118]. In one study, dogs
with hemangiosarcoma (𝑛𝑛 𝑛 𝑛𝑛) were signi�cantly more
likely to have detectable concentrations of plasma VEGF
compared to healthy dogs (𝑛𝑛 𝑛 𝑛𝑛) [119], although the
same groupwere not able to demonstrate amarked diﬀerence
in VEGF concentration between body cavity eﬀusions asso-
ciated with malignant versus nonmalignant diseases [120].
VEGF is a target for some of the newly licensed tyrosine
kinase inhibitors includingmasitinibmesylate (Masivet—AB
Science) and it has recently been shown that masitinib causes
a dose-dependent-cell death in canine haemangiosarcoma
cell lines [121]—further implicating a role for VEGF in
canine haemangiosarcoma.
Phosphatase and Tensin Homolog Deleted from Chro-
mosome 10 (PTEN) is a tumour suppressor gene which
is inactivated in many human cancers [122]. PTEN also
inhibits angiogenesis, possibly by regulating VEGF gene
expression via the P13K pathway [123, 124]. To determine
the role of PTEN in the origin or progression of canine
hemangiosarcoma, Dickerson et al. [125] �rstly examined by
immunohistochemistry the expression of CD31 (endothelial
marker), PTEN, VEGF, p27AKt, and p-AKT in sections from
12 haemangiosarcomas and 5 benign splenic haematomas
and observed some abnormalities in PTEN expression in
the tumours. Using cell lines established from some of
these tumours the same group identi�ed mutations of PTEN
in the C-terminal domain that may aﬀect the subcellular
localisation and stability of the protein [125].ey speculated
that constitutive activation of P13K or loss of PTEN func-
tion might establish autocrine growth loops that promote
autonomous growth and transformation of endothelial cells
[122, 126]. However the PTEN mutation alone does not fully
explain the increased levels of VEGF and other angiogenesis
promoting growth factors (platelet derived growth factor and
basic �broblast growth factor) thought to be elaborated by
haemangiosarcoma cells, or the role of the in�ammatory
cells frequently associated with these tumours [125]. Gene
expression pro�ling has shown canine hemangiosarcoma
to have a gene signature suggesting that in�ammatory and
angiogenic pathways play a signi�cant role in its patho-
genesis [127]. Genes expressed at signi�cantly higher levels
in haemangiosarcomas than osteosarcoma, non-Hodgkin’s
lymphoma, and leukaemia included VEGFA, TIMP-1, FN-1,
ADAM9, PDGFC,MMP14, TNF𝛼𝛼, and acid ceramidase.
Gene expression pro�ling of canine hemangiosarcoma
has also shown signi�cant breed diﬀerences segregating
hemangiosarcomas derived from golden retrievers from
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hemangiosarcoma in other breeds, with contributions
from transcription factors, survival factors, and from pro-
in�ammatory and angiogenic genes. VEGF Receptor 1 was
preferentially enriched in tumours from golden retrievers
versus other breeds [113], suggesting that heritable factors
mould gene expression phenotypes and consequently
biological behavior. e high incidence of hemangiosarcoma
in golden retrievers in the USA appears to be a relatively
recent phenomenon, as the golden retriever was not reported
to be over-represented in a study from the University of
Pennsylvania in 1988 [109]. Furthermore hemangiosarcoma
does not appear to be particularly prevalent in the breed in the
UK, indeed the data from the insured dog study [12] shows
golden retrievers to be less at risk of hemangiosarcoma
than all other breeds pooled (unpublished data). is is
particularly interesting because in a study investigating
genetic diversity among four common breeds sampled in
the US and Europe, the golden retriever showed a high
level of genetic diﬀerence between European and American
subpopulations allowing them to separate into two distinct
populations in clustering analyses corresponding to their
geographical origins [128]. Whereas less diﬀerentiation
was seen in the Bernese mountain dog and very little in
rottweilers or �at-coated retrievers from the two continents.
is result is partly due to breed popularity and population
size. e golden retriever is a very popular breed with more
than 42,000 American Kennel Club registrations and 8,000
UK Kennel Club registrations, such that there is a large
gene pool on both continents and mixing between the two
populations is rare. In contrast the �at-coated retriever
popularity in the UK declined following the �rst world war
leaving a small gene pool from which modern dogs derive;
the breed still has a relatively small population size worldwide
which limits genetic variation within the breed regardless of
geographical origin. Not only does this geographic variation
in the genetics of certain breeds indicate the importance of
taking account of population substructure in genetic studies
using worldwide sampling of pure-bred dogs, the genetic
diﬀerences between the European and North American
golden retriever could also be key to understanding the
aetiology of hemangiosarcoma in the breed.
5. Mast Cell Tumour
Mast cell tumours (MCTs) are common tumours of the
canine skin, estimated to represent 7–21 percent of all skin
tumours in this species [15, 129, 130]. In the UK, MCT is
the secondmost common caninemalignancy, aer so tissue
sarcoma with an incidence of 129 per 100,000 insured dogs
per year [12]. Cutaneous MCTs are typically solitary lesions
but their clinical appearance can be variable and dogs can
develop more than one unrelated MCT [131].
e boxer and bull dog breeds including bullmastiﬀs,
Boston terriers, and Staﬀordshire bull terriers are reported
to show an increased risk of developing MCT and it has
been postulated that this might be linked to a common
ancestry [132]. ese breeds have now been shown to
cluster closely phylogenetically [26]. Rhodesian ridgebacks,
pugs, weimaraners, Labrador retrievers, beagles, and golden
T 3: Breeds over- and underrepresented in a recent American
survey of breed association to canine mast cell tumours [130].
Dogs overrepresented Dogs underrepresented
Boxer German shepherd dog collie
Rhodesian ridgeback Toy Poodle
Vizsla Chihuahua
Boston terrier Lhasa Apso
Weimaraner Miniature poodle
Chinese Shar-Pei Siberian Husky
Bullmastiﬀ Yorkshire terrier
Dutch Pug Rottweiler
Labrador retriever Great Dane
American Staﬀordshire terrier Doberman pinscher
Golden retriever Dachshund
English setter American cocker spaniel
English pointer Mixed
retrievers have also been reported to be at increased risk
[13]. A phenomenon of occurrence of mast cell tumours in
young Shar-Pei dogs was reported from one US veterinary
pathology laboratory in 1995. From a total number of 802
submissions diagnosed as MCT, 18 were from Shar-Peis and
5 of these were in dogs less than 2 years of age. Poorly
diﬀerentiated (Grade III) tumours were more common
in younger dogs [133]. Another recently published North
American study considered the breed distribution of various
canine cutaneous tumours, includingMCT, and documented
not only those breed over-represented for the disease but
also those at reduced risk [130] (Table 3). In our clinic
(Cambridge, UK) Labrador retrievers, golden retrievers, and
Staﬀordshire bull terriers all appear over-represented (in
comparison to the general Hospital population) whilst Ger-
man shepherd dogs, cocker spaniels, border collies, cavalier
King Charles spaniels, and west Highland white terriers are
under-represented [134].
Mast cell tumours show very variable clinical behavior
and interestingly this may be in�uenced by breed. Although
boxer dogs and bulldog breeds are at higher risk of developing
MCTs, these breeds of dog tend to have low grade, less
aggressive tumours, as is also the case for pug dogs [135].
Labrador retrievers tend to have more aggressive tumours
and golden retrievers are at risk of developing multiple
tumours [131].
Despite a wealth of clinical studies on treatment and
prognostic indicators in canine mast cell tumours (review
[136]) there is very little published on the molecular genetics
of these tumours. Alterations in the p53 tumour suppressor
pathway have been identi�ed in some canineMCTs but TP53
sequencing in a small number of cases did not reveal any
mutations [137].
Recent work has implicated the stem cell factor receptor
(KIT) as having a role in the aetiology of canine MCTs [138].
KIT is normally expressed on haematopoteiic cells and mast
cells. It consists of an extracellular ligand-binding domain, a
transmembrane region, and a cytoplasmic tail with tyrosine
kinase activity. Activation of the KIT signal transduction
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pathway plays a role in the growth and development of
normal mast cells. KIT is encoded by the protooncogene c-
KIT, dysregulation of which occurs in many human cancers.
In 1996, London and others demonstrated expression of
KIT on malignant mast cells derived from 4 spontaneous
canine MCTs and subsequently reported internal tandem
duplications in exon 11 of c-KIT in approximately 30 percent
of canine MCTs [139]. Other studies have shown muta-
tions in the juxtamembrane domain of c-KIT in dogs with
MCTs, mainly within exon 11, with duplications, deletions
and substitutions being described [140–146]. Several studies
reported a signi�cant association between mutation and
higher grade of tumour [142, 143, 145]. To date nomutations
have been identi�ed within the canine c-KIT gene away from
the juxtamembrane domain, and in particular no mutations
have ever been identi�ed in the c-KIT kinase domain in
canine MCT [146]. is is in contrast to mast cell disease
in people, where the most common mutation is a single
nucleotide substitution resulting in a single amino acid sub-
stitution in the kinase domain. Internal tandem duplications
have not been reported in the c-KIT gene of people.
e presence of c-KIT mutations in only a proportion
of mast cell tumours suggests that although mutations in
this gene may be responsible for the development of some
mast cell tumours, it is likely that mutational events in
other genes are involved in the carcinogenesis of many
mast cell tumours which are yet to be identi�ed. Tumour
suppressor in lung cancer-1 (TSLC1) is a tumour-suppressor
gene coding for an adhesion molecule that is involved in
normal mast cell to mast cell, and mast cell to �broblast
interactions [147] Loss of TSLC1 expression is associated
with a poor prognosis in various human tumours, including
non-small cell lung cancer, breast, prostate, oesophageal and
gastric tumours [148–150] and has been shown to correlate
with grade in canine MCTs [151]. In humans, mutations
in the mismatch repair (MMR) genes give rise to Lynch
syndrome, an inherited predisposition to early onset cancer,
especially intestinal adenocarcinoma and skin cancer [152].
MMR expression was investigated immunohistochemically
in mast cell tumours from young dogs of predisposed breeds
versus old dogs of “non-MCT” predisposed breeds, but no
signi�cant diﬀerences were observed, suggesting that MMR
gene defects are not involved in the pathogenesis of canine
mast cell tumours [153].
6. Lymphoma/Leukaemia
Lymphoma is the most common haematopoietic malignancy
in the dog. Dog breed has been shown to play a role in the
epidemiology of lymphoma with several studies showing a
signi�cantly higher relative risk for boxers, bullmastiﬀ and
bulldog breeds compared to other breeds [9, 14, 154, 155].
Other breeds identi�ed with increased relative risk include
basset hound, St Bernard, Scottish terrier, Airedale terrier,
Bouvier des Flandres, Labrador retriever, and rottweiler [14,
156]. Familial associations with lymphoma have also been
reported; nine of 59 bullmastiﬀs from 3 households died
due to lymphoma over a 3-year period with most of the
dogs that died also having a close ancestor that had also
developed lymphoma [154]. Clustering of lymphoma has also
been reported in related rottweilers and three directly related
Otterhounds [157].
Interrogation of the data on a population of insured dogs
in the UK showed a signi�cant breed eﬀect with the boxer,
bulldog, and bull mastiﬀ breeds all having a high incidence
of lymphoma in certain age ranges, with the English springer
spaniel, golden retriever, and rottweiler breeds showing some
indication of excess lymphoma incidence over expectation
at certain age ranges—Table 4 [158]. In a study of just
over 600 dogs diagnosed with lymphoma in France over 1
year, boxers, setters, and cocker spaniels were signi�cantly
over-represented, and a possible predisposition in rottweilers
and Beauce shepherd dogs was also reported [159]. ese
authors also examined distribution of immunophenotype
of lymphoma by breed and demonstrated that boxer dogs
showed a signi�cant predilection for T-cell lymphoma but
were underrepresented among centroblastic polymorphic
lymphomas. Other breeds also appeared predisposed to
speci�c immunophenotypes, with B-cell lymphoma pre-
dominant in German shepherd dogs and probably in the
rottweiler.Whilst this study also demonstrated an association
of canine lymphoma with waste incinerators, polluted sites,
and radioactive waste, the strong breed associations with
immunophenotype and histological subtypes also support a
genetic aetiology.
It has recently been shown that the prevalence of subtypes
of lymphoma also varies with breed or breed group. A
distinct B-cell and T-cell prevalence of lymphoproliferative
disease by breed was reported in North America; 1263 dogs
representing 87 breeds, whose samples had been submitted
for PARR analysis—clonal rearrangement of immunoglobu-
lin heavy chain or T-cell receptor y chain—showed breed-
speci�c susceptibility to develop B-cell or T-cell tumours.
Boxers showed increased risk of developing T-cell tumours
as did the “Spitz” breeds and Asian “lap” dogs, whereas
border collies, basset hounds, cocker spaniels, and dober-
mans were aﬀected by predominantly B-cell tumours [160].
Because it is retained in related breed groups (e.g., Spitz-
type dogs and Asian “lap” dogs) the elevated risk for T-
cell lymphoproliferative disease may have arisen ancestrally,
whereas increased risk of B cell disease may stem from
diﬀerent risk factors or combinations which arose during
the process of breed selection. e boxer T-cell lymphoma
has been further classi�ed as being predominantly of TCR-
alpha/beta+, CD4+ (helper) T-cells with lymphoblastic (high
grade) morphology [161]. is strong breed association with
diﬀerent tumour subtypes may go some way to explaining
diﬀerences in response to chemotherapy and survival time
by breed which have been observed in some clinical studies
[162].
Using CGH analysis on a subset of these tumours, the
same study [160] identi�ed unique patterns of chromosomal
gains and losses that segregated speci�cally with B-cell
tumours and T-cell tumours (as previously identi�ed by
[163]) indicating that consistent genetic abnormalities are
associated with diﬀerent tumour types and thus lending
weight to the hypothesis that there is a heritable risk for devel-
opment of canine lymphoma. A deletion of chromosome 14
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T 4: Patterns of excess lymphoma by breed and age, comparing the observed numbers of lymphoma cases per breed, over four (quartile)
age ranges, with expected numbers computed from age incidence.
Age ≤ 3 4 ≤ Age ≤ 6 7 ≤ Age ≤ 9 10 ≤ Age ≤ 14 No dogs by breedO E O E O E O E
Border collie 1 0.37 0 0.47 1 0.68 1 0.93 2378
Boxer 1 1.06 2 1.05 4∗ 0.75 3¶ 0.52 5628
Bulldog 3∗ 0.38 0 0.24 0 0.10 0 0.006 1720
Bullmastiﬀ 0 0.21 3§ 0.17 0 0.09 0 0.016 1075
CKCS 0 0.71 1 1.15 2 1.08 0 0.85 4529
Cocker spaniel 0 0.95 1 1.16 1 1.06 0 0.90 5568
Crossbred 2 1.01 1 2.06 4 4.03 4 5.13 8855
Dalmatian 1 0.37 0 0.34 0 0.20 0 0.20 1973
Doberman 1 0.34 0 0.30 0 0.43 1 0.54 2006
English springer spaniel 0 0.72 0 0.87 1 0.89 3 0.93 4308
German shepherd dog 0 2.14 1 2.36 1 2.33 1 1.82 12157
Golden retriever 5¶ 1.02 3 2.78 1 2.40 6 2.86 11348
Irish setter 0 0.16 1¶ 0.31 0 0.22 0 0.26 1123
Labrador retriever 2 2.84 2 3.20 2 2.89 1 3.02 16259
Miniature schnauzer 0 0.17 0 0.20 1 0.18 0 0.16 1007
Old English sheepdog 0 0.18 1 0.29 1 0.27 0 0.26 1086
Rottweiler 0 0.45 0 0.32 2 0.44 0 0.38 2446
Staﬀordshire bull terrier 0 0.51 0 0.39 1 0.47 1 0.38 2844
West Highland white terrier 0 1.07 0 1.15 0 0.99 1 0.81 6134
Other breeds 6 6.5 11 8.22 5 7.48 5 7.05 38240
Total 130684
O: observed, E: expected.
∗Individually P ≤ 0.01 by Poisson distribution.
§Individually P ≤ 0.001 by Poisson distribution.
¶Individually P ≤ 0.05 by Poisson distribution.
Table from [158].
was exclusively seen in diﬀuse B-cell lymphoma and occurred
in 7 out of 7 golden retrievers but only in 13% (4 of 31) of
dogs from other breeds. omas et al. [164] have recently
reported the results of a genome-wide survey of tumour-
associated CNAs through array-based comparative genomic
hybridisation analysis in 150 cases of canine non-Hodgkin
lymphoma in predominantly three breeds of dog: boxers,
Labrador retrievers, and golden retrievers. Interrogation of
the recurrent CNAs identi�ed revealed an extensive catalog
of chromosomal regions and genes presenting with recurrent
DNA copy number imbalance, within which are key genes
previously associated with a range of human malignancies;
copy number loss of CDNK2A/B occurred in 20/36 T-cell
lymphoma cases and was more frequent in high grade than
low grade cases. e CNA associated most signi�cantly with
B cell lymphoma was a highly recurrent deletion of a discrete
region on chromosome 26 (74/106 cases) which encompasses
the canine immunoglobulin lambda locus. With regard to
breed, no signi�cant correlations were found within canine B
cell lymphoma suggesting that B cell lymphoma in diﬀerent
breeds shows a highly conserved genomic copy number
status, whereas the cytogenetic pro�les of T-cell lymphoma
were more strongly in�uenced by the genetic background of
the patient. Seven individual loci (on chromosomes 6, 12,
20, and 31) showed highly signi�cant association with breed,
each demonstrating an elevated incidence of copy number
gain in boxers with T-cell lymphoma [164].
7. Melanoma
Melanocytic tumours are relatively common in dogs; they
account for 4% of cutaneous tumours [13] and represent one
of the most common oral malignancies in the dog [165–
167]. Ocular and subungual variants are also described [168].
Canine melanocytic neoplasms vary widely in behavior;
oral/mucosal forms are usuallymalignant and provide a good
model for the human mucosal melanoma [4], although a
small proportion of tumours at this site are well diﬀerentiated
and follow a more benign course [169]. Cutaneous and
ocular tumours are usually benign, but tumours of the eyelid
and nail bed (subungual) are usually malignant. Despite
these generalisms, it should be acknowledged that the bio-
logical behavior of canine melanocytic neoplasms can vary
widely and although many studies have evaluated various
prognostic markers, an accurate prognostic classi�cation
for these tumours has yet to be established [170, 171].
Cutaneous melanoma occurs more commonly in dogs with
heavily pigmented skin, with Schnauzers (both miniature
and standard) and Scottish terriers at increased risk [13].
Small breeds especially cocker spaniels and poodles and dogs
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with heavily pigmented oral mucosa are reported to be at
greater risk of oral melanoma [165, 172]. A more recent
study of canine oral melanomas showed the Chow Chow,
golden retriever, and Pekingese/Poodle mix breeds to be
overrepresented, whereas the boxer and German shepherd
breeds were under represented [173]. It is not clear whether
these breed predilections re�ect an underlying genetic risk
or merely re�ect heavy pigmentation in some breeds, or
a combination of the two. However, breed and familial
clustering does support underlying genetic risk factors for
melanoma [168]. Furthermore, one study has reported that
breedmay have some prognostic signi�cance with more than
75% of melanocytic neoplasms exhibiting benign behavior
in the doberman and miniature Schnauzer, in contrast to
more than 85% of melanocytic neoplasms being malignant
in the miniature poodle [174], although tumour site may be
a confounding factor in these results.
In humans sunlight exposure is an established environ-
mental factor involved in the pathogenesis of cutaneous
malignant melanoma [175]; however 6 to 14% of melanoma
patients have a family history of melanoma, and it appears
there are complex environmental-genetic interactions in such
cases. Familial cases tend to be younger, to have a higher
number of moles and to develop multiple primary tumours
[176]. It has been shown that there are at least two genes
involved in familial melanoma in humans, the tumour sup-
pressors CDKN2A(p16) and CDK4. Families with germline
mutation in CDKN2A are also prone to pancreatic cancer
[177, 178]. A number of pathways and genetic mutations
have been identi�ed in nonfamilial cutaneous melanoma;
these include activating BRAF or NRAS mutations resulting
in hyperactivation of the mitogen-activated protein kinase
(MAPK) pathway [179] and loss or mutation of PTEN, a neg-
ative regulator of the P13K pathway [180]. Recent genome
wide association studies have identi�ed a number of loci
associated with nonfamilial melanoma and many mutations
have also been identi�ed through genome sequencing [181–
183], but the functional role of these mutations and variants
within these loci is not known and it is likely that many
other genes and environmental interactions, involved in the
pathogenesis of melanoma.
e role of tumour suppressors has been evaluated in
canine melanoma. In one study using canine melanoma
cell lines and tumour tissue samples, the loss or signi�cant
reduction in p16 expression was the most common abnor-
mality found in 6/7 cell lines and 21/26 tumour samples
[184]. Loss or signi�cant reduction of PTEN expression was
also seen in 4/7 cell lines and in 13/27 tumour samples.
Changes in other tumour suppressors TP53, Rb, and p21
were also detected, suggesting that loss of tumour suppressor
function is a common occurrence in canine melanoma. is
study included both dermal and oral melanomas; 14 tumours
were benign and 11 malignant but the abnormalities in p16
occurred with equal frequency in both benign andmalignant
tumours, suggesting that inactivation of this pathway is a crit-
ical step in the pathogenesis ofmelanoma. Loss of the tumour
suppressor gene products, p21/Waf1 and p53, has previously
been demonstrated in a benign multicentric melanoma from
a male Gordon setter [185]. More recently dysregulation of
the Wnt/beta catenin signal pathway has been reported in
18 canine cutaneous melanomas, demonstrated by abnormal
intracellular accumulation and increased expression of beta
catenin [186]. MicroRNA pro�les have been examined in
canine melanoma tissues and human and canine melanoma
cell lines and microRNAs 145 and 205 have been identi�ed
as tumour suppressors in both canine and human melanoma
cell lines [187, 188]. Other studies have examined KIT
expression in cutaneous melanocytic tumours [189] and oral
malignant melanomas [190], Cyclooxygenase-2 expression
[191, 192], expression of matrix metalloproteinases [193],
and Ki67 expression [194] in various canine melanomas but
more as prognostic indicators than as clues to the pathogene-
sis of these tumours. It is clear that canine melanoma oﬀers a
relevant model for the human disease and work is ongoing to
elucidate further genetic abnormalities that contribute to the
pathogenesis of the disease.
8. Mammary Tumours
Tumours of the mammary glands are the most common
tumour to aﬀect entire bitches representing between 50−70%
of all tumour types [18, 195]. A standardised incidence rate of
205/100,000 dogs/year has been reported in a population of
insured dogs in theUK [12] and in a Swedish study of insured
dogs that the overall rate of mammary tumour development
was 111 dogs per 10,000 dog years at risk (DAYR) [196].Mean
age of onset is approximately 8 years. It is well established that
ovarian hormone stimulation increases the risk of mammary
tumour development in dogs as in other species (including
humans) and in the bitch, ovariohysterectomy prior to 2 years
of age greatly reduces the risk of mammary tumours in later
life [10, 197].
e incidence of canine mammary tumours does vary by
breed but breeds reported to be at risk vary between diﬀerent
studies and diﬀerent geographical locations. Poodles (toy and
miniature), spaniels (English springer, cocker, and Brittany),
Puli, English setter, pointers, German shepherd, Maltese ter-
rier, Yorkshire terrier, and dachshund have all been reported
to be predisposed [198]. In the Swedish study where the
overall mammary tumour rate was 111 dogs per 10,000
DAYR the English springer spaniel, doberman pinscher, and
boxer showed signi�cantly increased incidence rates of 319,
297, and 256 per 10,000 DAYR, respectively, whereas the
rough haired collie showed signi�cantly reduced risk of 5 per
10,000 DAYR [196]. It should be noted that very few bitches
are routinely neutered in Sweden, so mammary tumours
are common [3]. A population based study of mammary
tumours in Norwegian dogs showed boxers, cocker spaniels,
English springer spaniels, and dachshunds to have the highest
relative risk of mammary tumour [195]. A study in Japan
reported a lower incidence of malignancy in mammary
tumours from small breed dogs [199]. is variation in
incidence of mammary tumour risk between breeds suggests
a signi�cant heritable genetic component to the disease in
dogs. A proportion of humanbreast cancer is familial; women
who have inherited mutations in the BRCA1 or BRCA2
(BRCA 1/2) genes have substantially increased risk of breast
cancer [45, 46] but it is recognised that mutations in these
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genes only account for a small part, approximately 10%,
of the total inherited eﬀect [200]. Furthermore BRCA1/2
mutation is rare in cases of sporadic breast cancer [201].
Four further genes, FGFR2, LSP1, MAP3K1, and TOX3,were
associated with a mild increase in risk of breast cancer in a
GWAS [202]; however over 50% of breast cancers occur in
women who do not carry these higher risk genotypes. Breast
cancer risk is currently believed to be polygenic with liability
conferred by a large number of loci, each contributing a small
eﬀect [203, 204]. Oncogenes reported to play an early role in
sporadic breast cancer includeMYC, CCND1 (Cyclin D), and
ERBB2 (HER2/neu) [201]. To date the increasingly powerful
molecular techniques available to sequence breast cancer
have not been able to elucidate speci�c genetic solutions
but rather have highlighted the substantial genetic diversity
underlying this common disease [205].
In contrast to the vast number of gene expression stud-
ies in human breast cancer relatively few gene expression
studies have been published on canine mammary tumours,
most studies having focused on speci�c genes or receptors.
A variable proportion of canine mammary tumours have
been reported to contain mutations in TP53 [206, 207]
and studies have shown an association between the level
of COX-2 expression, malignant phenotype, and prognosis
[208]. A recent comparative study of gene expression in
human breast and canine mammary tumours and normal
mammary tissue observed a signi�cant overlap of genes
deregulated in the tumour samples, as compared to their
normal counterparts [209], and pathway analysis of the
gene expression data revealed many cancer related pathways,
to be similarly perturbed including the P13/AKT, KRAS,
PTEN WNT-beta catenin pathways and the MAPK cascade
(Table 5). ese �ndings con�rm and support the value
of canine mammary cancer as a model for human breast
carcinogenesis [7, 209]. Althoughmammary tumours are one
of the targets being studies by a European consortium of
canine geneticists and clinicians (LUPA), no publications to
date have reported diﬀerential gene expression underlying
susceptibility to mammary cancer by breed [38]. However
BRCA1 and BRCA2 have been associated with mammary
tumours in English springer spaniels in Sweden. Ten human
breast cancer genes were evaluated for association with
mammary tumours in 212 mammary tumour cases and
143 controls by genotyping SNPs. BRCA1 and BRCA2 were
signi�cantly associated with mammary tumours and the
association was stronger to BRCA1 in malignant tumours. A
borderline association was seen for FGFR2 [210]. e same
group also investigated the role of the dog leucocyte antigen
(DLA) system as a genetic risk factor in the aetiology of
canine mammary tumours in English springer spaniels, and
by genotyping the polymorphic exon 2 of DLA class II loci,
identi�ed a signi�cant association between a rare protective
haplotype of MCH class II and the incidence of mammary
tumours in this population of 363 Spaniels, 218 cases and 145
healthy controls [211]. Not only do these �ndings support the
concept that MHC class II molecules play a critical role in
tumour surveillance but that immune response to cancermay
be in�uenced by genotype. A high interbreed and relatively
low intrabreed variation in MHC alleles and haplotypes has
T 5: Comparative analysis of the role of critical genes and
signalling pathways involved in the carcinogenesis of human breast
cancer and canine mammary tumor.
Human breast cancer Canine mammarytumor
Gene sets/signaling
pathways
P13K/AKT Upregulation Upregulation
KRAS Upregulation Upregulation
PTEN Downregulation Downregulation
Wnt∗b catenin Upregulation Upregulation
MAPK cascade Upregulation Upregulation
BRCA1 Downregulation Downregulation
BRCA2 Upregulation Upregulation
P53 Downregulation Downregulation
Table modi�ed from Pinho et al., 2012 [7], and based mainly on data from
Uva et al., 2009 [209].
been documented in over 80 diﬀerent breeds of dog, and
it has been suggested that this variation could provide an
explanation for interbreed variation in immune response to
vaccines, viruses, and other infections and possibly cancer
[212, 213].
9. Other Epithelial Malignancies, Carcinomas
In contrast to the high prevalence of lung and large bowel
cancer in the human population, particularly in the Western
World, carcinomas of the lung and large bowel are relatively
uncommon in the canine population. A number of tumour
registries and clinical case studies have highlighted breed
predispositions for carcinomas arising at other sites, as
listed in Table 6. Many of these are really just anecdotal
observations, the underlying genetic basis of which has rarely
been investigated; however a few are worthy of note.
Canine anal sac gland carcinoma (ASGC) is a relatively
uncommon malignancy arising from the apocrine glands
in the walls of the anal sacs. is tumour is invasive and
metastatic in nature and is oen associated with a parane-
oplastic hypercalcaemia. Although ASGC may arise in any
breed of dog the English cocker spaniel and to a lesser
degree other spaniel types (English springer and cavalier King
Charles) have been reported to be predisposed to develop-
ment of this tumour [214]. Predisposing genetic factors have
yet to be elucidated but an association between ASGC and
dog leucocyte antigen DQB1 has been demonstrated in the
English cocker spaniel [215]. e allele distribution in DLA
loci DAL-DRB1, -DQA1, and DQB1 was compared between
42 cases and 75 controls; there was no diﬀerence in allele
distribution in DLA-DRB1 while a signi�cant diﬀerence
was obtained for DLA-DQA1 and DQB1 alleles, with the
DLA-DQB1-00701 allele having a higher frequency in cases
than controls [215]. Interestingly a similar DLA-DQB1 allele
association has been shown in the English cocker spaniel and
immune-mediated hemolytic anaemia [216]. It is not known
at this time whether the allele itself has a causative eﬀect
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T 6: Additional breed predilections to assorted tumor types.
Tumour type Breeds showingpredilection References
Anal sac gland
carcinoma
English cocker spaniel
[214]English springerspaniel
Cavalier King Charles
Squamous cell
carcinoma digit
Giant schnauzer [217]
Standard poodle [219]
Transitional cell
carcinoma,
bladder
Scottish terrier
[220]West Highland white
terrier
Lower UT carcinoma
Shetland sheepdog
[221]Airedale terrier
Beagle
Prostatic carcinoma
Doberman pinscher
[11]
Shetland sheepdog
Scottish terrier
Beagle German short
haired pointer
Airedale terrier
Norwegian elkhound
Gastric carcinoma Rough Collie [230]
Belgian shepherd [41]
yroid carcinoma
Golden retriever
[231]Beagle
Siberian Husky
Nasal cavity carcinoma Collie [232]
Shetland sheepdog
Aortic/Carotid body
tumors
(paraganglioma)
English bulldog
[233]Boxer
Boston terrier
Brain tumors
Boxer
[223]Golden retriever
Boston terrier
Testicular tumors
[234]Sertoli cell tumor Shetland sheepdog
Collie
Seminoma Norwegian elkhound
on development of disease, perhaps through altered immune
function, or whether it is an indirect association as a marker
locus with a causative locus located in its vicinity.
Other breeds or types of dog have been associated
with less common carcinomas, for example, squamous cell
carcinoma of the digit appears to have a predilection for large
black dogs including giant Schnauzers and standard poodles
[217, 218], who interestingly cluster quite closely on the phy-
logenetic tree [26]. A familial association has been reported
in giant schnauzers [219]. Scottish Terriers have been shown
to be at 19-fold increased risk of transitional cell carcinoma of
the bladder compared with mixed breeds, the cause of which
is not known but perhaps represents genetic predisposition
through diﬀerences inmetabolic and detoxi�cation pathways
[220]. In addition to the Scottish terrier, Airedale terriers
and beagles have also been identi�ed as being predisposed
to lower urinary tract tumours, whereas German shepherd
dogs appear to be under-represented [221]. In contrast to
human prostatic carcinoma, which is androgen dependent,
prostate cancer has been reported to occur more commonly
in neutered than intact male dogs, possibly because a high
proportion of canine prostatic carcinomas are transitional
cell origin as opposed to adenocarcinoma [222]. Although
neutering status is a strong risk factor for canine prostatic
cancer, breed predisposition has been demonstrated with
dobermann pinschers, Shetland sheepdogs, Scottish terriers,
beagles, German shorthaired pointers, Airedale terriers, and
Norwegian elkhounds all having a statistically signi�cantly
increased odds of having prostatic cancer of any histology
independent of neutering status [11].
10. Brain Tumours
Intracranial neoplasia is quite well described in the dog
where the most common primary CNS tumour is menin-
gioma, followed by glial tumours (astrocytoma and oligo-
dendroglioma). Choroids plexus tumours, medulloblastoma,
neuroblastoma, and ependymomas occur less frequently.
In a postmortem study of 173 dogs, golden retrievers and
boxers were at increased risk to develop primary intracranial
tumours relative to their frequency in the general Hospital
population [223]. Brachycephalic breeds have previously
been reported to be prone to development of glioma, but in
this study only boxers and Boston terriers were more likely to
have an astrocytoma, oligodenroglioma, or undiﬀerentiated
glioma than another type of primary intracranial neoplasm.
Boxers account for nearly 50% of dogs with brain tumours
presented for radiotherapy at the Cancererapy Unit, Cam-
bridge, and appear equally aﬀected by glioma and pituitary
macroadenoma (unpublished data).
11. Multiple Primary Tumours
is paper has highlighted strong breed predispositions to
certain types of cancer and breeds that are prone tomore than
one tumour type. In reviewing the more recent gene expres-
sion literature it is apparent that tumour suppressor genes,
particularly CDKN2A, CDNK2B, and PTEN, are implicated
in the pathogenesis ofmany canine tumours, but to date there
is little evidence to demonstrate that defects in these pathways
are inherited in the susceptible breeds. Recently a germline
mutation in the mesenchymal-epithelial transition factor
(MET) protooncogene was found in approximately 70% of
rottweiler dogs, a breed predisposed to several types of cancer
[224]. is supports the concept that particular dog breeds
may carry germline mutations that contribute to high rates
of cancer in a manner similar to heritable, cancer-associated
mutations in humans. Inherited defects in tumour suppressor
genes have been associated with increased risk of early onset
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cancer and development of multiple primary tumours in
humans, notably TP53 and Li-Fraumeni syndrome [44]. e
literature contains a number of case reports of multiple
tumours in individual dogs, for example, simultaneous aortic
body tumour and pulmonary histiocytic sarcoma in a �at-
coated retriever [225], but only recently has a detailed analysis
of dogs presenting with multiple distinct types of neoplasia
been published [226]. ese represented just 3%, 53 of 1722
dogs presented to the oncology service at Colorado State
University Veterinary Medical Centre; although no breed
or sex predisposition was apparent, dogs with mast cell
tumour, malignant melanoma, and thyroid carcinoma were
signi�cantly over-represented.
12. Conclusions
Most of this review has focused discussion on the breeds of
dog associated with an increased risk of developing cancer
and breed associations recognised in common tumours. It
should be acknowledged that for most forms of cancer the
aetiology is likely to be multifactorial and although genetics
are important environmental factors such as chemical expo-
sure [227] and hormonal/metabolic factors have been shown
to increase the risk of development of certain tumours.
e domestic dog has been bred selectively for many
years to accentuate traits that are desirable in the eyes of
the breeder. Each dog breed with a speci�c pool of alleles
represents a genetic isolate, facilitating the identi�cation of
susceptibility alleles in dogs breeds as compared to humans.
Pure-bred dogs allow the identi�cation of rare variants in the
whole canine population because they have been accidentally
selected in a given dog breed, and for multifactorial dis-
eases such as cancer, the impact of environmental exposure
can be analysed against a reasonably homogenous genetic
background. us the fact that diﬀerent breeds of dog have
diﬀerent predilections to diﬀerent forms of cancer is not only
interesting but could provide a very important insight into
the genetic aetiology of many forms of the disease. is is
particularly important in a disease like cancer, where the
complex disease phenotypes are likely to have developed
from a combination of multiple genetic risk factors, each
with relatively weak penetrance. It could be that the genetic
architecture of cancer in predisposed breeds such as the
Bernese, boxer, and golden retriever is basically the same as
in other breeds with other tumours. e diﬀerence is that in
the former, the risk conferred by one or more predisposing
alleles could be higher. Whether the same alleles predispose
to various types of cancer in Bernese, boxer, and golden
retriever, or whether diﬀerent loci, segregating in each one of
those breeds, are responsible for the diﬀerent tumour types,
is an interesting question which remains to be answered.
Much has been made of the many problems associated
with pedigree dogs in the popular and veterinary press [228,
229]; it is therefore somewhat ironic that as a result of these
problems the pedigree dog provides an idealmodel to identify
phenotype/genotype relationships relevant to human disease.
e sequencing of the canine genome [29] along with the
new genomic tools and resources now available for the study
of the dog has allowed workers to start to analyse complex
diseases such as cancer. As this review has shown, the dog
is already proving to be a valuable model for this purpose
and further well designed and conducted population based
studies into breed-related canine cancers would provide an
important platform to take forward future genetic research.
Abbreviations
GWAS: Genome wide association study/ies
CNA: Copy number abnormality
TCR: T-cell receptor
PARR: PCR for antigen receptor rearrangements
PCR: Polymerase chain reaction
VEGF: Vascular endothelial growth factor
CGH: Comparative genomic hybridization
SNP: Single nucleotide polymorphism
DLA: Dog leucocyte antigen
MHC: Major histocompatibility complex
ASGC: Anal sac gland carcinoma
GRCA: Golden retriever club of america
DYAR: Dog years at risk.
Acknowledgments
e author would like to thank Dr. Liz Murchison and Dr.
Jesus Aguirre-Hernandez for their helpful comments on this
paper.
References
[1] V. J. Adams, K. M. Evans, J. Sampson, and J. L. N. Wood,
“Methods and mortality results of a health survey of purebred
dogs in the UK,” Journal of Small Animal Practice, vol. 51, no.
10, pp. 512–524, 2010.
[2] R. T. Bronson, “Variation in age at death of dogs of diﬀerent
sexes and breeds,” American Journal of Veterinary Research, vol.
43, no. 11, pp. 2057–2059, 1982.
[3] B. N. Bonnett and A. Egenvall, “Age patterns of disease and
death in insured Swedish dogs, Cats and Horses,” Journal of
Comparative Pathology, vol. 142, no. 1, pp. S33–S38, 2010.
[4] E. G. MacEwen, “Spontaneous tumors in dogs and cats: models
for the study of cancer biology and treatment,” Cancer and
Metastasis Reviews, vol. 9, no. 2, pp. 125–136, 1990.
[5] D. M. Vail and E. G. MacEwen, “Spontaneously occurring
tumors of companion animals as models for human cancer,”
Cancer Investigation, vol. 18, no. 8, pp. 781–792, 2000.
[6] C. Khanna, K. Lindblad-Toh, D. Vail et al., “e dog as a cancer
model,” Nature Biotechnology, vol. 24, no. 9, pp. 1065–1066,
2006.
[7] S. S. Pinho, S. Carvalho, J. Cabral, C. A. Reis, and F. Gärt-
ner, “Canine tumors: a spontaneous animal model of human
carcinogenesis,” Translational Research, vol. 159, no. 3, pp.
165–172, 2012.
[8] L. Marconato, M. E. Gelain, and S. Comazzi, “e dog as a
possible animal model for human non-Hodgkin lymphoma: a
review,” Hematological Oncology. In press.
[9] K. Arnesen, H. Gamlem, E. Glattre, J. Grondalen, L. Moe,
and K. Nordstoga, “e Norwegian Canine Cancer Register
1990–1998: report from the project “Cancer in the Dog”,”
ISRN Veterinary Science 17
European Journal of Companion Animal Practice, vol. 11, pp.
159–169, 2001.
[10] R. Schneider, C. R. Dorn, and D. O. Taylor, “Factors in�uencing
canine mammary cancer development and postsurgical sur-
vival,” Journal of the National Cancer Institute, vol. 43, no. 6, pp.
1249–1261, 1969.
[11] J. N. Bryan, M. R. Keeler, C. J. Henry, M. E. Bryan, A. W. Hahn,
and C. W. Caldwell, “A population study of neutering status as
a risk factor for canine prostate cancer,” Prostate, vol. 67, no. 11,
pp. 1174–1181, 2007.
[12] J. M. Dobson, S. Samuel, H. Milstein, K. Rogers, and J. L. N.
Wood, “Canine neoplasia in the UK: estimates of incidence
rates from a population of insured dogs,” Journal of Small
Animal Practice, vol. 43, no. 6, pp. 240–246, 2002.
[13] M. H. Goldschmidt and F. S. Shofer, Skin Tumours of the Cat
and Dog, Pergamon Press, New York, NY, USA, 1992.
[14] W. A. Priester and F. W. McKay, “e occurrence of tumors in
domestic animals,”National Cancer InstituteMonograph, no. 54,
article 158, 1980.
[15] C. R. Dorn, D. O. Taylor, R. Schneider, H. H. Hibbard, and
M. R. Klauber, “Survey of animal neoplasms in Alameda and
ContraCosta Counties, California. II. Cancermorbidity in dogs
and cats from Alameda County,” Journal of the National Cancer
Institute, vol. 40, no. 2, pp. 307–318, 1968.
[16] B. N. Bonnett, A. Egenvall, P. Olson, and A. Hedhammar,
“Mortality in insured Swedish dogs: rates and causes of death in
various breeds,” Veterinary Record, vol. 141, no. 2, pp. S40–S44,
1997.
[17] R. J. Reid-Smith, B. N. Bonnett, S. W. Martin, S. A. Kruth, A.
Abrams-Ogg, and M. J. Hazlett, “e incidence of neoplasia in
the canine and feline patient populations of private veterinary
practices in southern Ontario,” in Proceedings of the 9th sym-
posium of the International Society for Veterinary Epidemiology
and Economics, pp. 935–955, Colorado, Colo, USA, August
2000.
[18] D. F. Merlo, L. Rossi, C. Pellegrino et al., “Cancer incidence
in pet dogs: �ndings of the animal tumor registry of Genoa,
Italy,” Journal of Veterinary Internal Medicine, vol. 22, no. 4, pp.
976–984, 2008.
[19] M. Vascellari, E. Baioni, G. Ru, A. Carminato, and F. Mutinelli,
“Animal tumour registry of two provinces in northern Italy:
incidence of spontaneous tumours in dogs and cats,” BMC
Veterinary Research, vol. 5, article 39, 2009.
[20] L. B. Brønden, S. S. Nielsen, N. To, and A. T. Kristensen, “Data
from the Danish veterinary cancer registry on the occurrence
and distribution of neoplasms in dogs in Denmark,” Veterinary
Record, vol. 166, no. 19, pp. 586–590, 2010.
[21] A. Egenvall, B. N. Bonnett, A. Hedhammar, and P. Olson, “Mor-
tality in over 350,000 insured Swedish dogs from 1995–2000:
II. Breed-speci�c age and survival patterns and relative risk for
causes of death,” Acta Veterinaria Scandinavica, vol. 46, no. 3,
pp. 121–136, 2005.
[22] H. F. Proschowsky, H. Rugbjerg, and A. K. Ersbøll, “Morbidity
of purebred dogs in Denmark,” Preventive Veterinary Medicine,
vol. 58, no. 1-2, pp. 53–62, 2003.
[23] A. R. Michell, “Longevity of British breeds of dog and its rela-
tionships with sex, size, cardiovascular variables and disease,”
Veterinary Record, vol. 145, no. 22, pp. 625–629, 1999.
[24] Kennel Club/British Small Animal Veterinary Association
Scienti�c Committee. Purebred Dog Health Survey 2004,
http://www.thekennelclub.org.uk/item/549.
[25] H. G. Parker, A. L. Shearin, and E. A. Ostrander, “Man’s best
friend becomes biology’s best in show: genome analyses in the
domestic dog,” Annual Review of Genetics, vol. 44, pp. 309–336,
2010.
[26] B. M. Vonholdt, J. P. Pollinger, K. E. Lohmueller et al.,
“Genome-wide SNP and haplotype analyses reveal a rich
history underlying dog domestication,” Nature, vol. 464, no.
7290, pp. 898–902, 2010.
[27] R. K. Wayne and B. M. Vonholdt, “Evolutionary genomics of
dog domestication,” Mammalian Genome, vol. 23, no. 1-2, pp.
3–18, 2012.
[28] H. G. Parker, N. B. Sutter, and E. A. Ostrander, “Understanding
genetic relationships among purebred dogs: the PhyDo project,”
in e Dog and Its Genome, O. Giger and K. Lindbland-Toh,
Eds., chapter 9, pp. 141–157, Cold Spring Harbour Laboratory
Press, New York, NY, USA, 2005.
[29] K. Lindblad-Toh, C. M. Wade, T. S. Mikkelsen et al., “Genome
sequence, comparative analysis and haplotype structure of the
domestic dog,” Nature, vol. 438, no. 7069, pp. 803–819, 2005.
[30] M. M. Gray, J. M. Granka, C. D. Bustamante et al., “Linkage
disequilibrium and demographic history of wild and domestic
canids,” Genetics, vol. 181, no. 4, pp. 1493–1505, 2009.
[31] F. C. F. Calboli, J. Sampson, N. Fretwell, and D. J. Balding,
“Population structure and inbreeding from pedigree analysis of
purebred dogs,” Genetics, vol. 179, no. 1, pp. 593–601, 2008.
[32] E. Cadieu, M. W. Neﬀ, P. Quignon et al., “Coat variation in the
domestic dog is governed by variants in three genes,” Science,
vol. 326, no. 5949, pp. 150–153, 2009.
[33] A. R. Boyko, “e domestic dog: man’s best friend in the
genomic era,” Genome Biology, vol. 12, no. 2, article 216, 2011.
[34] D. F. Patterson, “Conpanion animal medicine in the age of
medical genetics,” Journal of Veterinary Internal Medicine, vol.
14, pp. 1–9, 2000.
[35] D. R. Sargan, “IDID: inherited Diseases in Dogs: web-based
information for canine inherited disease genetics,”Mammalian
Genome, vol. 15, no. 6, pp. 503–506, 2004.
[36] N. B. Sutter, M. A. Eberle, H. G. Parker et al., “Extensive
and breed-speci�c linkage disequilibrium in Canis familiaris,”
Genome Research, vol. 14, no. 12, pp. 2388–2396, 2004.
[37] A. L. Shearin and E. A. Ostrander, “Leading the way: canine
models of genomics and disease,” DMM Disease Models and
Mechanisms, vol. 3, no. 1-2, pp. 27–34, 2010.
[38] A. S. Lequarré, L. Andersson, C. André et al., “LUPA: a
European initiative taking advantage of the canine genome
architecture for unravelling complex disorders in both human
and dogs,”Veterinary Journal, vol. 189, no. 2, pp. 155–159, 2011.
[39] E. Cadieu and E. A. Ostrander, “Canine genetics oﬀers new
mechanisms for the study of human cancer,” Cancer Epidemiol-
ogy Biomarkers and Prevention, vol. 16, no. 11, pp. 2181–2183,
2007.
[40] P. N. Olson, “Using the canine genome to cure cancer and other
diseases,”eriogenology, vol. 68, no. 3, pp. 378–381, 2007.
[41] E. Scanziani, A. M. Giusti, M. Gualtieri et al., “Gastric carci-
noma in the Belgian shepherd dog,” Journal of Small Animal
Practice, vol. 32, pp. 465–469, 1991.
[42] J. C. Phillips, B. Stephenson, M. Hauck, and J. Dillberger,
“Heritability and segregation analysis of osteosarcoma in the
Scottish deerhound,” Genomics, vol. 90, no. 3, pp. 354–363,
2007.
[43] H. G. Parker, L. V. Kim, N. B. Sutter et al., “Genetic structure
of the purebred domestic domestic dog,” Science, vol. 304, no.
5674, pp. 1160–1164, 2004.
18 ISRN Veterinary Science
[44] U. Tabori and D. Malkin, “Risk strati�cation in cancer pre-
disposition syndromes: lessons learned from novel molecular
developments in Li-Fraumeni syndrome,” Cancer Research, vol.
68, no. 7, pp. 2053–2057, 2008.
[45] M. C. King, J. H. Marks, and J. B. Mandell, “Breast and ovarian
cancer risks due to inheritedmutations in BRCA1 and BRCA2,”
Science, vol. 302, no. 5645, pp. 643–646, 2003.
[46] A. C. Antoniou, P. D. P. Pharoah, D. F. Easton, and D. G. Evans,
“BRCA1 and BRCA2 cancer risks,” Journal of Clinical Oncology,
vol. 24, no. 20, pp. 3312–3313, 2006.
[47] L. Moe, H. Gamlem, T. J. Jónasdóttir, and F. Lingaas, “Renal
microcystic tubular lesions in two 1-year-old dogs—an early
sign of hereditary renal cystadenocarcinoma?” Journal of Com-
parative Pathology, vol. 123, no. 2-3, pp. 218–221, 2000.
[48] T. J. Jónasdóttir, C. S. Mellersh, L. Moe et al., “Genetic mapping
of a naturally occurring hereditary renal cancer syndrome in
dogs,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 97, no. 8, pp. 4132–4137, 2000.
[49] M. L. Nickerson, M. B. Warren, J. R. Toro et al., “Mutations in a
novel gene lead to kidney tumors, lung wall defects, and benign
tumors of the hair follicle in patients with the Birt-Hogg-Dubé
syndrome,” Cancer Cell, vol. 2, no. 2, pp. 157–164, 2002.
[50] V. K. Aﬀolter and P. F. Moore, “Localized and disseminated
histiocytic sarcoma of dendritic cell origin in dogs,” Veterinary
Pathology, vol. 39, no. 1, pp. 74–83, 2002.
[51] L. E. Craig, M. E. Julian, and J. D. Ferracone, “e diagnosis
and prognosis of synovial tumors in dogs: 35 cases,” Veterinary
Pathology, vol. 39, no. 1, pp. 66–73, 2002.
[52] P. F. Moore, e UC Davies Canine Histiocytosis site,
http://www.histiocytosis.ucdavis.edu/.
[53] R. J. M. M. oolen, J. H. VOS, J. S. Van Der Linde-Sipman
et al., “Malignant �brous histiocytomas in dogs and cats: an
immunohistochemical study,” Research in Veterinary Science,
vol. 53, no. 2, pp. 198–204, 1992.
[54] R. L. Kerlen and M. J. Hendrick, “Malignant �brous histio-
cytoma and malignant histiocytosis in the dog—convergent
or divergent phenotypic diﬀerentiation?” Veterinary Pathology,
vol. 33, no. 6, pp. 713–716, 1996.
[55] J. S. Morris, E. F. McInnes, D. E. Bostock, T. M. Hoather,
and J. M. Dobson, “Immunohistochemical and histopathologic
features of 14 malignant �brous histiocytomas from Flat-
Coated Retrievers,” Veterinary Pathology, vol. 39, no. 4, pp.
473–479, 2002.
[56] A. K. Fulmer and G. E. Mauldin, “Canine histiocytic neoplasia:
an overview,” Canadian Veterinary Journal, vol. 48, no. 10, pp.
1041–1050, 2007.
[57] G. A. Padgett, B. R. Madewell, E. T. Keller, L. Jodar, and
M. Packard, “Inheritance of histiocytosis in Bernese mountain
dogs,” Journal of Small Animal Practice, vol. 36, no. 3, pp. 93–98,
1995.
[58] J. S. Morris, D. E. Bostock, E. F. Mcinnes, T. M. Hoather, and
J. M. Dobson, “Histopathological survey of neoplasms in �at-
coated retrievers, 1990 to 1998,” Veterinary Record, vol. 147, no.
11, pp. 291–295, 2000.
[59] J. Dobson, T. Hoather, T. J. McKinley, and J. L. N. Wood, “Mor-
tality in a cohort of �at-coated retrievers in the UK,” Veterinary
and Comparative Oncology, vol. 7, no. 2, pp. 115–121, 2009.
[60] P. F. Moore and A. Rosin, “Malignant histiocytosis of Bernese
mountain dogs,” Veterinary Pathology, vol. 23, no. 1, pp. 1–10,
1986.
[61] A. Rosin, P. Moore, and R. Dubielzig, “Malignant histiocytosis
in Bernese Mountain dogs,” Journal of the American Veterinary
Medical Association, vol. 188, no. 9, pp. 1041–1045, 1986.
[62] I. K. Ramsey, J. S. McKay, H. Rudorf, and J. M. Dobson,
“Malignant histiocytosis in three Bernese mountain dogs,”
Veterinary Record, vol. 138, no. 18, pp. 440–444, 1996.
[63] S. Rossi, M. E. Gelain, and S. Comazzi, “Disseminated histio-
cytic sarcoma with peripheral blood involvement in a Bernese
Mountain dog,” Veterinary Clinical Pathology, vol. 38, no. 1, pp.
126–130, 2009.
[64] J. Abadie, B. Hédan, E. Cadieu et al., “Epidemiology, pathology,
and genetics of histiocytic sarcoma in the Bernese mountain
dog breed,” Journal of Heredity, vol. 100, supplement 1, pp.
S19–27, 2009.
[65] F. Constantino-Casas, D. Mayhew, T. M. Hoather, and J.
M. Dobson, “e clinical presentation and histopathologic-
immunohistochemical classi�cation of histiocytic sarcomas in
the Flat Coated retriever,” Veterinary Pathology, vol. 48, no. 3,
pp. 764–771, 2011.
[66] J. Fidel, I. Schiller, B. Hauser et al., “Histiocytic sarcomas in Flat-
Coated Retrievers: a summary of 37 cases (November 1998-
March 2005),” Veterinary and Comparative Oncology, vol. 4, pp.
63–74, 2006.
[67] K. A. Skorupski, C. A. Cliﬀord, M. C. Paoloni et al., “CCNU
for the treatment of dogs with histiocytic sarcoma,” Journal of
Veterinary Internal Medicine, vol. 21, no. 1, pp. 121–126, 2007.
[68] K. M. Rassnick, A. S. Moore, D. S. Russell et al., “Phase II,
open lable trial of single-agent CCNU in dogs with previously
untreated histiocytic sarcoma,” Journal of Veterinary Internal
Medicine, vol. 24, no. 6, pp. 1528–1531, 2010.
[69] P. F. Moore, V. K. Aﬀolter, and W. Vernau, “Canine
hemophagocytic histiocytic sarcoma: a proliferative disorder of
CD11d+ macrophages,” Veterinary Pathology, vol. 43, no. 5, pp.
632–645, 2006.
[70] J. Dobson, E. Villiers, A. Roulois et al., “Histiocytic sarcoma of
the spleen in �at-coated retrievers with regenerative anaemia
and hypoproteinaemia,” Veterinary Record, vol. 158, no. 24, pp.
825–829, 2006.
[71] L. Van Kuijk, K. van Ginkel, M. Brealey et al., “Peri-articular
histiocytic sarcoma and synovial cell sarcoma in Bernese
Mountain dogs: a retrospective investgation of the prevalence
of these tumors in association with previously diseased joints,”
in Proceedings 8th International Bernese Mountain dog Health
Seminar, p. 80, 2011.
[72] L. C. Shaiken, S. M. Evans, and M. H. Goldschmidt, “Radio-
graphic �ndings in canine malignant histiocytosis,” Veterinary
Radiology, vol. 32, no. 5, pp. 237–2242, 1991.
[73] D. W. Hayden, D. J. Waters, B. A. Burke, and J. C. Manivel,
“Disseminated malignant histiocytosis in a golden retriever:
clinicopathologic, ultrastructural, and immunohistochemical
�ndings,” Veterinary Pathology, vol. 30, no. 3, pp. 256–264,
1993.
[74] B. Kohn, P. Arnold, and B. Kaser-Hotz, “Malignant histiocytosis
of the dog: 26 cases (1989–1992),” Kleintierpraxis, vol. 38, pp.
409–424, 1993.
[75] R.M. Schultz, S. M. Puchalski, M. Kent, and P. F. Moore, “Skele-
tal lesions of histiocytic sarcoma in nineteen dogs,” Veterinary
Radiology and Ultrasound, vol. 48, no. 6, pp. 539–543, 2007.
[76] L. Nielsen, S. N. Andreasen, S. D. Andersen, and A. T.
Kristensen, “Malignant histiocytosis and other causes of death
in Bernese mountain dogs in Denmark,”Veterinary Record, vol.
166, no. 7, pp. 199–202, 2010.
ISRN Veterinary Science 19
[77] B. Hedan, R. omas, A. Motsinger-Reif et al., “Molecular
cytogenetic characterization of canine histiocytic sarcoma: a
spontaneous model for human histiocytic cancer identi�es
deletion of tumor suppressor genes and highlights in�uence of
genetic background on tumor behavior,” BMC Cancer, vol. 11,
article 201, 2011.
[78] A. L. Shearin, B. Hedan, E. Cadieu et al., “eMTAP-CDKN2A
locus confores susceptibility to a naturally occurring canine
cancer,” Cancer Epidemiology Biomarkers & Prevention, vol. 21,
no. 7, pp. 1019–1027, 2012.
[79] M. H. Dreyling, D. Roulston, S. K. Bohlander, J. Vardiman,
and O. I. Olopade, “Codeletion of CDKN2 and MTAP genes
in a subset of non-hodgkin’s lymphoma may be associated with
histologic transformation from low-grade to diﬀuse large-cell
lymphoma,” Genes Chromosomes and Cancer, vol. 22, no. 1, pp.
72–78, 1998.
[80] J. Gil and G. Peters, “Regulation of the INK4b-ARF-INK4a
tumour suppressor locus: all for one or one for all,” Nature
Reviews Molecular Cell Biology, vol. 7, no. 9, pp. 667–677, 2006.
[81] J. Aguirre-Hernández, B. S. Milne, C. Queen et al., “Disrup-
tion of chromosome 11 in canine �brosarcomas highlights
an unusual variability of CDKN2B in dogs,” BMC Veterinary
Research, vol. 5, article 27, 2009.
[82] C. J. McNeill, B. Overley, F. S. Shofer et al., “Characterization
of the biological behaviour of appendicular osteosarcoma in
Rottweilers and a comparisonwith other breeds: a review of 258
dogs,” Veterinary and Comparative Oncology, vol. 5, no. 2, pp.
90–98, 2007.
[83] J. A. Rosenberger, N. V. Pablo, and P. C. Crawford, “Prevalence
of and intrinsic risk factors for appendicular osteosarcoma
in dogs: 179 cases (1996–2005),” Journal of the American
Veterinary Medical Association, vol. 231, no. 7, pp. 1076–1080,
2007.
[84] G. Ru, B. Terracini, and L. T. Glickman, “Host related risk
factors for canine osteosarcoma,” Veterinary Journal, vol. 156,
no. 1, pp. 31–39, 1998.
[85] J. Kirpensteijn, M. Kik, G. R. Rutteman, and E. Teske, “Prog-
nostic signi�cance of a newhistologic grading system for canine
osteosarcoma,”Veterinary Pathology, vol. 39, no. 2, pp. 240–246,
2002.
[86] E. G.Ma, J. Kutzke, J. Carew et al., “c-Met tyrosine kinase recep-
tor expression and function in human and canine osteosarcoma
cells,” Clinical and Experimental Metastasis, vol. 20, no. 5, pp.
421–430, 2003.
[87] E. G.Ma, J. Pastor, J. Kutzke et al., “IGF-1 receptor contributes to
the malignant phenotype in human and canine osteosarcoma,”
Journal of Cellular Biochemistry, vol. 92, no. 1, pp. 77–91, 2004.
[88] D. M. Cooley, B. C. Beranek, D. L. Schlittler, N. W. Glickman,
L. T. Glickman, and D. J. Waters, “Endogenous gonadal hor-
mone exposure and bone sarcoma risk,” Cancer Epidemiology
Biomarkers and Prevention, vol. 11, no. 11, pp. 1434–1440, 2002.
[89] S. Mendoza, T. Konishi, W. S. Dernell, S. J. Withrow, and
C. W. Miller, “Status of the p53, Rb and Mdm2 genes in
canine osteosarcoma,” Anticancer Research, vol. 18, no. 6 A, pp.
4449–4453, 1998.
[90] R. A. Levine and M. A. Fleischli, “Inactivation of p53 and
retinoblastoma family pathways in canine osteosarcoma cell
lines,” Veterinary Pathology, vol. 37, no. 1, pp. 54–61, 2000.
[91] W.Misdorp and A. A. M. Hart, “Some prognostic and epidemi-
ologic factors in canine osteosarcoma,” Journal of the National
Cancer Institute, vol. 62, no. 3, pp. 537–545, 1979.
[92] R. S. Brodey and D. A. Abt, “Results of surgical treatment in
65 dogs with osteosarcoma,” Journal of the American Veterinary
Medical Association, vol. 168, no. 11, pp. 1032–1035, 1976.
[93] A. Egenvall, A. Nødtvedt, and H. von Euler, “Bone tumors in
a population of 400, 000 insured Swedish dogs up to 10 y of
age: incidence and survival,” Canadian Journal of Veterinary
Research, vol. 71, no. 4, pp. 292–299, 2007.
[94] W. S. Dernell, N. P. Ehrhart, R. C. Straw, and D. Vail, “Tumors
of the skeletal system,” inWithrow andMacEwen’s Small Animal
Clinical Oncology, S. J. Withrow and D. M. Vail, Eds., Chapter
23, pp. 540–582, Saunders, Elsevier, 2007.
[95] N. B. Sutter, C. D. Bustamante, K. Chase et al., “A single IGF1
allele is a major determinant of small size in dogs,” Science, vol.
316, no. 5821, pp. 112–115, 2007.
[96] L. K. Lord, J. E. Yaissle, L. Marin, and C. G. Couto, “Results of a
web-based health survey of retired racing greyhounds,” Journal
of Veterinary Internal Medicine, vol. 21, no. 6, pp. 1243–1250,
2007.
[97] M. Paoloni and C. Khanna, “Translation of new cancer treat-
ments from pet dogs to humans,”Nature Reviews Cancer, vol. 8,
no. 2, pp. 147–156, 2008.
[98] S. J.Withrow and R.M.Wilkins, “Cross talk from pets to people:
translational osteosarcoma treatments,” ILAR Journal, vol. 51,
no. 3, pp. 208–213, 2010.
[99] E. Morello, M. Martano, and P. Buracco, “Biology, diagnosis
and treatment of canine appendicular osteosarcoma: similar-
ities and diﬀerences with human osteosarcoma,” Veterinary
Journal, vol. 189, no. 3, pp. 268–277, 2010.
[100] M. C. Scott, A. L. Sarver, K. J. Gavin et al., “Molecular subtypes
of osteosarcoma identi�ed by reducing tumor heterogeneity
through an interspecies comparative approach,” Bone, vol. 49,
no. 3, pp. 356–367, 2011.
[101] A. Y. Angstadt, A. Motsinger-Reif, R.omas et al., “Character-
ization of canine osteosarcoma by array comparative genomic
hybridization and RT-qPCR: signatures of genomic imbalance
in canine osteosarcoma parallel the human counterpart,” Genes
Chromosomes and Cancer, vol. 50, no. 11, pp. 859–874, 2011.
[102] C. Khanna, X.Wan, S. Bose et al., “emembrane-cytoskeleton
linker ezrin is necessary for osteosarcoma metastasis,” Nature
Medicine, vol. 10, no. 2, pp. 182–186, 2004.
[103] M. Paoloni, S. Davis, S. Lana et al., “Canine tumor cross-species
genomics uncovers targets linked to osteosarcoma progression,”
BMC Genomics, vol. 10, article 625, 2009.
[104] G. T. Selvarajah, J. Kirpensteijn, M. E. van Wolferen, N. A. S.
Rao, H. Fieten, and J. A. Mol, “Gene expression pro�ling of
canine osteosarcoma reveals genes associated with short and
long survival times,”Molecular Cancer, vol. 8, article 72, 2009.
[105] L. E. O’Donoghue, A. A. Ptitsyn, D. A. Kamstock, J. Siebert,
R. S. omas, and D. L. Duval, “Expression pro�ling in canine
osteosarcoma: identi�cation of biomarkers and pathways asso-
ciated with outcome,” BMC Cancer, vol. 10, article 506, 2010.
[106] R. omas, H. J. Wang, P. C. Tsai et al., “In�uence of
genetic background on tumor karyotypes: evidence for breed-
associated cytogenetic aberrations in canine appendicular
osteosarcoma,” Chromosome Research, vol. 17, no. 3, pp.
365–377, 2009.
[107] M. Koch, G. P. Nielsen, and S. S. Yoon, “Malignant tumors
of blood vessels: angiosarcomas, hemangioendotheliomas, and
hemangioperictyomas,” Journal of Surgical Oncology, vol. 97,
no. 4, pp. 321–329, 2008.
20 ISRN Veterinary Science
[108] H. Ward, L. E. Fox, M. B. Calderwood-Mays, A. S. Hammer,
and C. G. Couto, “Cutaneous hemangiosarcoma in 25 dogs: a
retrospective study,” Journal of Veterinary InternalMedicine, vol.
8, no. 5, pp. 345–348, 1994.
[109] C. Prymak, L. J. McKee, M. H. Goldschmidt, and L. T. Glick-
man, “Epidemiologic, clinical, pathologic, and prognostic char-
acteristics of splenic hemangiosarcoma and splenic hematoma
in dogs: 217 cases (1985),” Journal of the American Veterinary
Medical Association, vol. 193, no. 6, pp. 706–712, 1988.
[110] N. O. Brown, A. K. Patnaik, and E. G. MacEwen, “Canine
hemangiosarcoma: retrospective analysis of 104 cases,” Journal
of the American Veterinary Medical Association, vol. 186, no. 1,
pp. 56–58, 1985.
[111] W. L. Spangler and M. R. Culbertson, “Prevalence, type,
and importance of splenic diseases in dogs: 1,480 cases
(1985–1989),” Journal of the American Veterinary Medical Asso-
ciation, vol. 200, no. 6, pp. 829–834, 1992.
[112] Golden Retriever Club of North America, http://www
.grca.org/pdf/health/CancerSamplesApril2011.pdf.
[113] B. A. Tamburini, S. Trapp, T. L. Phang, J. T. Schappa, L.
E. Hunter, and J. F. Modiano, “Gene expression pro�les of
sporadic canine hemangiosarcoma are uniquely associated with
breed,” PLoS ONE, vol. 4, no. 5, Article ID e5549, 2009.
[114] L. Nasir, G. R. Rutteman, S. W. J. Reid, C. Schulze, and D.
J. Argyle, “Analysis of p53 mutational events and MDM2
ampli�cation in canine so�-tissue sarcomas,” Cancer Letters,
vol. 174, no. 1, pp. 83–89, 2001.
[115] B. Mayr, S. Zwetkoﬀ, G. Schaﬀner, and M. Rei�nger, “Tumour
suppressor gene p53mutation in a case of haemangiosarcoma of
a dog,” Acta Veterinaria Hungarica, vol. 50, no. 2, pp. 157–160,
2002.
[116] K. Yonemaru, H. Sakai, M.Murakami et al., “e signi�cance of
p53 and retinoblastoma pathways in canine hemangiosarcoma,”
Journal of VeterinaryMedical Science, vol. 69, no. 3, pp. 271–278,
2007.
[117] J. Bartkova, J. Lukas, P. Guldberg et al., “e p16-cyclin
D/Cdk4-pRb pathway as a functional unit frequently altered in
melanoma pathogenesis,” Cancer Research, vol. 56, no. 23, pp.
5475–5483, 1996.
[118] H. Kumar, K. Heer, P. W. R. Lee et al., “Preoperative serum vas-
cular endothelial growth factor can predict stage in colorectal
cancer,” Clinical Cancer Research, vol. 4, no. 5, pp. 1279–1285,
1998.
[119] C. A. Cliﬀord, D. Hughes, M. W. Beal et al., “Plasma vascular
endothelial growth factor concentrations in healthy dogs and
dogs with hemangiosarcoma,” Journal of Veterinary Internal
Medicine, vol. 15, no. 2, pp. 131–135, 2001.
[120] C. A. Cliﬀord, D. Hughes, M. W. Beal, C. J. Henry, K. J.
Drobatz, and K. U. Sorenmo, “Vascular endothelial growth
factor concentrations in body cavity eﬀusions in dogs,” Journal
of Veterinary InternalMedicine, vol. 16, no. 2, pp. 164–168, 2002.
[121] S. E. Lyles, R. J. Milner, K. Kow, and M. E. Salute, “In vitro
eﬀects of the tyrosine kinase inhibitor, masitinib mesylate, on
canine hemangiosarcoma cell lines,” Veterinary and Compara-
tive Oncology, vol. 10, no. 3, pp. 223–235, 2012.
[122] L. C. Cantley and B. G. Neel, “New insights into tumor
suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway,” Proceedings of
the National Academy of Sciences of the United States of America,
vol. 96, no. 8, pp. 4240–4245, 1999.
[123] F. Gesbert, W. R. Sellers, S. Signoretti, M. Loda, and J. D. Grif-
�n, “BCR/ABL regulates expression of the cyclin-dependent
kinase inhibitor p27𝑘𝑘𝑘𝑘𝑘𝑘𝑘 through the phosphatidylinositol 3-
kinase/AKT pathway,”e Journal of Biological Chemistry, vol.
275, no. 50, pp. 39223–39230, 2000.
[124] D. Koul, R. Shen, A. Garyali, L. D. Ke, T. J. Liu, and W.
K. Yung, “MMAC/PTEN tumor suppressor gene regulates
vascular endothelial growth factor-mediated angiogenesis in
prostate cancer,” International Journal of Oncology, vol. 21, no.
3, pp. 469–475, 2002.
[125] E. B. Dickerson, R. omas, S. P. Fosmire et al., “Mutations of
phosphatase and tensin homolog deleted from chromosome 10
in canine hemangiosarcoma,” Veterinary Pathology, vol. 42, no.
5, pp. 618–632, 2005.
[126] B. H. Jiang, J. Z. Zheng, M. Aoki, and P. K. Vogt, “Phos-
phatidylinositol 3-kinase signaling mediates angiogenesis and
expression of vascular endothelial growth factor in endothelial
cells,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 97, no. 4, pp. 1749–1753, 2000.
[127] B. A. Tamburini, T. L. Phang, S. P. Fosmire et al., “Gene
expression pro�ling identi�es in�ammation and angiogenesis
as distinguishing features of canine hemangiosarcoma,” BMC
Cancer, vol. 10, article 619, 2010.
[128] P. Quignon, L. Herbin, E. Cadieu et al., “Canine population
structure: assessment and impact of intra-breed strati�cation on
SNP-based association studies,”PLoSONE, vol. 2, no. 12, Article
ID e1324, 2007.
[129] R. S. Brodey, “Canine and feline neoplasia,” Advances in Veteri-
nary Science and Comparative medicine, vol. 14, pp. 309–354,
1970.
[130] J. A. Villamil, C. J. Henry, J. N. Bryan et al., “Identi�cation of the
most common cutaneous neoplasms in dogs and evaluation of
breed and age distributions for selected neoplasms,” Journal of
the American VeterinaryMedical Association, vol. 239, no. 7, pp.
960–965, 2011.
[131] S.Murphy,A.H. Sparkes, A. S. Blunden,M. J. Brearley, andK.C.
Smith, “Eﬀects of stage and number of tumours on prognosis of
dogs with cutaneous mast cell tumours,” Veterinary Record, vol.
158, no. 9, pp. 287–291, 2006.
[132] J. A. Peters, “Canine mastocytoma: excess risk as related to
ancestry,” Journal of the National Cancer Institute, vol. 42, no.
3, pp. 435–443, 1969.
[133] D. M. Miller, “e occurrence of mast cell tumors in young
Shar-Peis,” Journal of Veterinary Diagnostic Investigation, vol. 7,
no. 3, pp. 360–363, 1995.
[134] J. W. Warland and J. M. Dobson, “e eﬀect of breed
and anatomic location on canine mast cell tumour clinical
behaviour,” in Proceeding of the WSAVA/ FECAVA/ BSAVA
World Congress, p. 538, Birmingham, UK, April 2012.
[135] E. A. McNeil, A. L. Prink, and TD. O’Brien, “Evaluation of
risk and clinical outcome of mast cell tumours in pug dogs,”
Veterinary and Comparative Oncology, vol. 4, pp. 2–28, 2006.
[136] J. M. Dobson and T. J. Scase, “Advances in the diagnosis and
management of cutaneous mast cell tumours in dogs,” Journal
of Small Animal Practice, vol. 48, no. 8, pp. 424–431, 2007.
[137] B. Mayr, M. Rei�nger, G. Brem, C. Feil, and W. Schleger,
“Cytogenetic, ras, and p53: studies in cases, of canine
neoplasms (hemangiopericytoma, mastocytoma, histiocytoma,
chloroma),” Journal of Heredity, vol. 90, no. 1, pp. 124–128,
1999.
[138] C. A. London, W. C. Kisseberth, S. J. Galli, E. N. Geissler, and
S. C. Helfand, “Expression of stem cell factor receptor (c-kit)
by the malignant mast cells from spontaneous canine mast cell
ISRN Veterinary Science 21
tumours,” Journal of Comparative Pathology, vol. 115, no. 4, pp.
399–414, 1996.
[139] C. A. London, S. J. Galli, T. Yuuki, Z. Q. Hu, S. C. Helfand, and
E. N. Geissler, “Spontaneous canine mast cell tumors express
tandemduplications in the proto-oncogene c-kit,”Experimental
Hematology, vol. 27, no. 4, pp. 689–697, 1999.
[140] Y. Ma, B. J. Longley, X. Wang, J. L. Blount, K. Langley,
and G. H. Caughey, “Clustering of activating mutations in
c-KIT’s juxtamembrane coding region in canine mast cell
neoplasms,” Journal of Investigative Dermatology, vol. 112, no.
2, pp. 165–170, 1999.
[141] M. J. Reguera, L. Ferrer, and R. M. Rabanal, “Evaluation of an
intron deletion in the c-kit gene of canine mast cell tumors,”
American Journal of Veterinary Research, vol. 63, no. 9, pp.
1257–1261, 2002.
[142] D. Zemke, B. Yamini, and V. Yuzbasiyan-Gurkan, “Mutations in
the juxtamembrane domain of c-KIT are associated with higher
grade mast cell tumors in dogs,” Veterinary Pathology, vol. 39,
no. 5, pp. 529–535, 2002.
[143] S. Downing, M. B. Chien, P. H. Kass, P. F. Moore, and C.
A. London, “Prevalence and importance of internal tandem
duplications in exons 11 and 12 of c-kit in mast cell tumors of
dogs,” American Journal of Veterinary Research, vol. 63, no. 12,
pp. 1718–1723, 2002.
[144] F. Riva, S. Brizzola, D. Stefanello, S. Crema, and L. Turin,
“A study of mutations in the c-kit gene of 32 dogs with
mastocytoma,” Journal of Veterinary Diagnostic Investigation,
vol. 17, no. 4, pp. 385–388, 2005.
[145] J. D. Webster, V. Yuzbasiyan-Gurkan, J. B. Kaneene, R. Miller,
J. H. Resau, andM. Kiupel, “e role of c-KIT in tumorigenesis:
evaluation in canine cutaneous mast cell tumors,” Neoplasia,
vol. 8, no. 2, pp. 104–111, 2006.
[146] J. D. Webster, M. Kiupel, and V. Yuzbasiyan-Gurkan, “Evalua-
tion of the kinase domain of c-KIT in canine cutaneous mast
cell tumors,” BMC Cancer, vol. 6, article 85, 2006.
[147] K. Watabe, A. Ito, Y. I. Koma, and Y. Kitamura, “IGSF4: a new
intercellular adhesion molecule that is called by three names,
TSLC1, SgIGSF and SynCAM, by virtue of its diverse function,”
Histology and Histopathology, vol. 18, no. 4, pp. 1321–1329,
2003.
[148] T. Fukami, H. Fukuhara, M. Kuramochi et al., “Promoter
methylation of the TSLC1 gene in advanced lung tumors and
various cancer cell lines,” International Journal of Cancer, vol.
107, no. 1, pp. 53–59, 2003.
[149] G. Heller, J. Geradts, B. Ziegler et al., “Downregulation of
TSLC1 and DAL-1 expression occurs frequently in breast
cancer,” Breast Cancer Research and Treatment, vol. 103, no. 3,
pp. 283–291, 2007.
[150] G. Tamura, “Alterations of tumor suppressor and tumor-related
genes in the development and progression of gastric cancer,”
World Journal of Gastroenterology, vol. 12, no. 2, pp. 192–198,
2006.
[151] F. Taylor, S. Murphy, T. Hoather, J. Dobson, and T. Scase,
“TSLC1 tumour-suppressor gene expression in caninemast cell
tumours,” Veterinary and Comparative Oncology, vol. 8, no. 4,
pp. 263–272, 2010.
[152] M. R. Hussein and G. S. Wood, “Microsatellite instability and
its relevance to cutaneous tumorigenesis,” Journal of Cutaneous
Pathology, vol. 29, no. 5, pp. 257–267, 2002.
[153] J. S. Munday, A. F. French, I. R. Gibson, and K. Gwynne,
“Widespread mismatch repair protein expression in canine
cutaneous mast cell tumors,” Veterinary Pathology, vol. 46, no.
2, pp. 227–232, 2009.
[154] D. E. Onions, “A prospective survey of familial canine lym-
phosarcoma,” Journal of the National Cancer Institute, vol. 72,
no. 4, pp. 909–91, 1984.
[155] C. Fournel-Fleury, F. Ponce, P. Felman et al., “Canine T-
cell lymphomas: a morphological, immunological, and clinical
study of 46 new cases,” Veterinary Pathology, vol. 39, no. 1, pp.
92–109, 2002.
[156] E. Teske, “Canine malignant lymphoma: a review and com-
parison with human non-Hodgkin’s lymphoma,” Veterinary
Quarterly, vol. 16, no. 4, pp. 209–219, 1994.
[157] E. Teske, J. P. de Vos, H. F. Egberink, and J. H. Vos, “Clustering
in canine malignant lymphoma,” Veterinary Quarterly, vol. 16,
no. 2, pp. 134–136, 1994.
[158] D. S. Edwards, W. E. Henley, E. F. Harding, J. M. Dobson, and J.
L. N.Wood, “Breed incidence of lymphoma in a UK population
of insured dogs,” Veterinary and Comparative Oncology, vol. 1,
no. 4, pp. 200–2206, 2003.
[159] M. Pastor, K. Chalvet-Monfray, T. Marchal et al., “Genetic
and environmental risk indicators in canine non-Hodgkin’s
lymphomas: breed associations and geographic distribution of
608 cases diagnosed throughout France over 1 year,” Journal of
Veterinary Internal Medicine, vol. 23, no. 2, pp. 301–310, 2009.
[160] J. F. Modiano, M. Breen, R. C. Burnett et al., “Distinct B-cell
and T-cell lymphoproliferative disease prevalence among dog
breeds indicates heritable risk,” Cancer Research, vol. 65, no. 13,
pp. 5654–5661, 2005.
[161] D. M. Lurie, R. J. Milner, S. E. Suter, and W. Vernau,
“Immunophenotypic and cytomorphologic subclassi�cation of
T-cell lymphoma in the boxer breed,” Veterinary Immunology
and Immunopathology, vol. 125, no. 1-2, pp. 102–110, 2008.
[162] L. D. Garrett, D. H. amm, R. Chun, R. Dudley, and D. M.
Vail, “Evaluation of a 6-month chemotherapy protocol with
no maintenance therapy for dogs with lymphoma,” Journal of
Veterinary Internal Medicine, vol. 16, no. 6, pp. 704–709, 2002.
[163] R. omas, K. C. Smith, E. A. Ostrander, F. Galibert, and
M. Breen, “Chromosome aberrations in canine multicentric
lymphomas detected with comparative genomic hybridisation
and a panel of single locus probes,”British Journal of Cancer, vol.
89, no. 8, pp. 1530–1537, 2003.
[164] R. omas, E. L. Seiser, A. Motsinger-Reif et al., “Re�ning
tumor-associated aneuploidy through “genomic recoding” of
recurrent DNA copy number aberrations in 150 canine non-
Hodgkin lymphomas,” Leukemia and Lymphoma, vol. 52, no. 7,
pp. 1321–1335, 2011.
[165] R. S. Brodey, “A clinical and pathiologic study of 130 neoplasms
of the mouth and pharynx in the dog,” American Journal of
Veterinary Research, vol. 21, pp. 787–812, 1960.
[166] R. F. Hoyt and S. J. Withrow, “Oral malignancy in the dog,”
Journal of the American Animal Hospital Association, vol. 20,
article 8392, 1984.
[167] L. B. Brønden, T. Eriksen, andA. T. Kristensen, “Oral malignant
melanomas and other head and neck neoplasms in Danish
dogs—data from the Danish Veterinary Cancer Registry,” Acta
veterinaria Scandinavica, vol. 51, article 54, 2009.
[168] S. H. Smith, M. H. Goldschmidt, and P. M. McManus, “A
comparative review of melanocytic neoplasms,” Veterinary
Pathology, vol. 39, no. 6, pp. 651–678, 2002.
[169] D. G. Esplin, “Survival of dogs following surgical excision of
histologically well-diﬀerentiated melanocytic neoplasms of the
22 ISRN Veterinary Science
mucous membranes of the lips and oral cavity,” Veterinary
Pathology, vol. 45, no. 6, pp. 889–896, 2008.
[170] W. L. Spangler and P. H. Kass, “e histologic and epidemio-
logic bases for prognostic considerations in canine melanocytic
neoplasia,” Veterinary Pathology, vol. 43, no. 2, pp. 136–149,
2006.
[171] R. C. Smedley, W. L. Spangler, D. G. Esplin et al., “Prognostic
markers for canine melanocytic neoplasms: a comparative
review of the literature and goals for future investigation,”
Veterinary Pathology, vol. 48, no. 1, pp. 54–72, 2011.
[172] C. R. Dorn and W. A. Priester, “Epidemiologic analysis of oral
and pharyngeal cancer in dogs, cats, horses, and cattle,” Journal
of the American Veterinary Medical Association, vol. 169, no. 11,
pp. 1202–1206, 1976.
[173] J. A. Ramos-Vara, M. E. Beissenherz, M. A. Miller et al., “Ret-
rospective study of 338 canine oral melanomas with clinical,
histologic, and immunohistochemical review of 129 cases,”
Veterinary Pathology, vol. 37, no. 6, pp. 597–608, 2000.
[174] B. Bolon, M. B. Calderwood Mays, and B. J. Hall, “Character-
istics of canine melanomas and comparison of histology and
DNA ploidy to their biologic behavior,” Veterinary pathology,
vol. 27, no. 2, pp. 96–102, 1990.
[175] R. Marks, “Epidemiology of melanoma,” Clinical and Experi-
mental Dermatology, vol. 25, no. 6, pp. 459–463, 2000.
[176] C. G. Ang, J. W. Kelly, L. Fritschi, and J. P. Dowling, “Char-
acteristics of familial and non-familial melanoma in Australia,”
Melanoma Research, vol. 8, no. 5, pp. 459–464, 1998.
[177] A. M. Goldstein, M. C. Fraser, J. P. Struewing et al., “Increased
risk of pancreatic cancer in melanoma-prone kindreds with
p16𝐼𝐼𝐼𝐼𝐼𝐼𝐼 mutations,”e New England Journal of Medicine, vol.
333, no. 15, pp. 970–974, 1995.
[178] M. H. Greene, “e genetics of hereditary melanoma and nevi:
1998 update,” Cancer, vol. 86, no. 11, pp. 2464–2477, 1999.
[179] K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson,
“NRAS and BRAF mutations arise early during melanoma
pathogenesis and are preserved throughout tumor prgression,”
Clinical Cancer Research, vol. 9, no. 17, pp. 6483–6488, 2003.
[180] P. Guldberg, P. or Straten, A. Birck, V. Ahrenkiel, A. F.
Kirkin, and J. Zeuthen, “Disruption of the MMAC1/PTEN
gene by deletion or mutation is a frequent event in malignant
melanoma,” Cancer Research, vol. 57, no. 17, pp. 3660–3663,
1997.
[181] D. T. Bishop, F. Demenais, M. M. Iles et al., “Genome-wide
association study identi�es three loci associatedwithmelanoma
risk,” Nature Genetics, vol. 41, no. 8, pp. 920–925, 2009.
[182] M. R. Gerstenblith, J. Shi, and M. T. Landi, “Genome-wide
association studies of pigmentation and skin cancer: a review
and meta-analysis,” Pigment Cell and Melanoma Research, vol.
23, no. 5, pp. 587–606, 2010.
[183] S. Turajlic, S. J. Furney, M. B. Lambros et al., “Whole
genome sequencing of matched primary and metastatic acral
melanomas,”GenomeResearch, vol. 22, no. 2, pp. 196–207, 2012.
[184] A. Koenig, S. R. Bianco, S. Fosmire, J. Wojcieszyn, and J. F.
Modiano, “Expression and signi�cance of p53, rb, p21/waf -1,
p16/ink-4a, andPTEN tumor suppressors in caninemelanoma,”
Veterinary Pathology, vol. 39, no. 4, pp. 458–472, 2002.
[185] M. G. Ritt, J. Wojcieszyn, and J. F. Modiano, “Functional loss of
p21/Waf-1 in a case of benign canine multicentric melanoma,”
Veterinary Pathology, vol. 35, no. 2, pp. 94–101, 1998.
[186] J. I. Han, D. Y. Kim, and K. J. Na, “Dysregulation of the
wnt/𝛽𝛽-catenin signaling pathway in canine cutaneous melan-
otic tumor,” Veterinary Pathology, vol. 47, no. 2, pp. 285–291,
2010.
[187] S. Noguchi, T. Mori, Y. Hoshino, N. Yamada, K. Maruo, and
Y. Akao, “MicroRNAs as tumour suppressors in canine and
human melanoma cells and as a prognostic factor in canine
melanomas,” Veterinary and Comparative Oncology. In press.
[188] S. Noguchi, T. Mori, Y. Hoshino et al., “Comparative study of
anti-oncogenicMicroRNA-145 in canine and humanmalignant
melanoma,” Journal of Veterinary Medical Science, vol. 74, no. 1,
pp. 1–8, 2012.
[189] J. Gomes, F. L. Queiroga, J. Prada, and I. Pires, “Study of c-kit
immunoexpression in canine cutaneous melanocytic tumors,”
Melanoma Research, vol. 22, no. 3, pp. 195–201, 2012.
[190] A. Murakami, T. Mori, H. Sakai et al., “Analysis of KIT
expression and KIT exon 11mutations in canine oral malignant
melanomas,” Veterinary and Comparative Oncology, vol. 9, no.
3, pp. 227–232, 2011.
[191] I. Pires, A. Garcia, J. Prada, and F. L. Queiroga, “COX-1
and COX-2 expression in canine cutaneous, oral and ocular
melanocytic tumours,” Journal of Comparative Pathology, vol.
143, no. 2-3, pp. 142–149, 2010.
[192] C. M. Mart�nez, C. Pe�a�el-Verd�, M. Vilafranca et al.,
“Cyclooxygenase-2 expression is related with localization, pro-
liferation, and overall survival in canine melanocytic neo-
plasms,” Veterinary Pathology, vol. 48, no. 6, pp. 1204–1211,
2011.
[193] M.-J. Docampo, J. Cabrera, R. M. Rabanal, and A. Bas-
sols, “Expression of matrix metalloproteinase-2 and -9 and
membrane-type 1 matrix metalloproteinase in melanocytic
tumors of dogs and canine melanoma cell lines,” American
Journal of Veterinary Research, vol. 72, no. 8, pp. 1087–1096,
2011.
[194] I. L. Bergin, R. C. Smedley, D. G. Esplin, W. L. Spangler, and M.
Kiupel, “Prognostic evaluation of ki67 threshold value in canine
oral melanoma,” Veterinary Pathology, vol. 48, no. 1, pp. 41–53,
2011.
[195] L. Moe, “Population-based incidence of mammary tumours
in some dog breeds,” Journal of Reproduction and Fertility.
Supplement, vol. 57, pp. 439–443, 2001.
[196] A. Egenvall, B. N. Bonnett, P. Öhagen, P. Olson, A. Hedhammar,
and H. Von Euler, “Incidence of and survival aer mammary
tumors in a population of over 80,000 insured female dogs in
Sweden from 1995 to 2002,” Preventive VeterinaryMedicine, vol.
69, no. 1-2, pp. 109–127, 2005.
[197] G. R. Rutteman, “Hormones and mammary tumour disease in
the female dog: an update,” In Vivo, vol. 4, no. 1, pp. 33–40, 1990.
[198] H. Von Euler, “Tumours of the mammary glands,” in BSAVA
Manual of Canine and Feline Oncology, J. Dobson and Lascelles,
Eds., chapter 16, pp. 237–247, BSAVA, 3rd edition, 2011.
[199] T. Itoh, K. Uchida, K. Ishikawa et al., “Clinicopathological
survey of 101 canine mammary gland tumors: diﬀerences
between small-breed dogs and others,” Journal of Veterinary
Medical Science, vol. 67, no. 3, pp. 345–347, 2005.
[200] P. D. P. Pharoah, A. C. Antoniou, D. F. Easton, and B. A. J.
Ponder, “Polygenes, risk prediction, and targeted prevention of
breast cancer,” e New England Journal of Medicine, vol. 358,
no. 26, pp. 2796–2803, 2008.
[201] P. Kenemans, R. A. Verstraeten, and R. H. M. Verheijen,
“Oncogenic pathways in hereditary and sporadic breast cancer,”
Maturitas, vol. 49, no. 1, pp. 34–43, 2004.
ISRN Veterinary Science 23
[202] D. F. Easton, K. A. Pooley, A. M. Dunning et al., “Genome-wide
association study identi�es novel breast cancer susceptibility
loci,” Nature, vol. 447, no. 7148, pp. 1087–1093, 2007.
[203] P. D. P. Pharoah, A. M. Dunning, B. A. J. Ponder, and D. F.
Easton, “Association studies for �nding cancer-susceptibility
genetic variants,” Nature Reviews Cancer, vol. 4, no. 11, pp.
850–860, 2004.
[204] M. Ghoussaini and P. D. P. Pharoah, “Polygenic susceptibility to
breast cancer: current state-of-the-art,” Future Oncology, vol. 5,
no. 5, pp. 689–701, 2009.
[205] P. J. Stephens, P. S. Tarpey, H. Davies et al., “e landscape of
cancer genes andmutational processes in breast cancer,”Nature,
vol. 486, no. 7403, pp. 400–404, 2012.
[206] L. L. Chu, G. R. Rutteman, J. M. C. Kong et al., “Genomic
organization of the canine p53 gene and its mutational status
in canine mammary neoplasia,” Breast Cancer Research and
Treatment, vol. 50, no. 1, pp. 11–25, 1998.
[207] S.Wakui, T.Muto, K. Yokoo et al., “Prognostic status of p53 gene
mutation in caninemammary carcinoma,”Anticancer Research,
vol. 21, no. 1, pp. 611–616, 2001.
[208] F. L. Queiroga, I. Pires, L. Lobo, and C. S. Lopes, “e role
of Cox-2 expression in the prognosis of dogs with malignant
mammary tumours,” Research in Veterinary Science, vol. 88, no.
3, pp. 441–445, 2010.
[209] P. Uva, L. Aurisicchio, J. Watters et al., “Comparative expression
pathway analysis of human and canine mammary tumors,”
BMC Genomics, vol. 10, article 135, 2009.
[210] P. J. Rivera, M. Melin, T. Biagi et al., “Mammary tumor
development in dogs is associated with BRCA1 and BRCA2,”
Cancer Research, vol. 69, no. 22, pp. 8770–8774, 2009.
[211] P. Rivera, Biochemical markers and genetic risk factors in canine
tumours [Ph.D. thesis], Swedish University of Agricultural
Sciences. Acta Universitatis Agriculturae Sueciae, 2010.
[212] L. J. Kennedy, A. Barnes, G. M. Happ et al., “Extensive
interbreed, but minimal intrabreed, variation of DLA class II
alleles and haplotypes in dogs,” Tissue Antigens, vol. 59, no. 3,
pp. 194–204, 2002.
[213] M. Hafskjold, L. J. Kennedy, W. E. R. Ollier, and B. Catchpole,
“.Restricted dog leucocyte antigen (DLA) genotypes in Rot-
tweiler dogs: could this cause poor responses to vaccination?”
in BSAVA Congress� Scienti�c Proceedings, p. 507, 2007.
[214] G. A. Polton, V. Mowat, H. C. Lee, K. A. McKee, and T. J. Scase,
“Breed, gender and neutering statuus of British dogs with anal
sac gland carcinoma,” Veterinary and Comparative Oncology,
vol. 4, pp. 125–1131, 2006.
[215] J. Aguirre-Hernández, G. Polton, L. J. Kennedy, and D. R.
Sargan, “Association between anal sac gland carcinoma and dog
leukocyte antigen-DQB1 in the English Cocker Spaniel,” Tissue
Antigens, vol. 76, no. 6, pp. 476–481, 2010.
[216] L. J. Kennedy, A. Barnes, W. E. R. Ollier, and M. J. Day,
“Association of a common dog leucocyte antigen class II
haplotype with canine primary immune-mediated haemolytic
anaemia,” Tissue Antigens, vol. 68, no. 6, pp. 502–508, 2006.
[217] C. J. Henry, W. G. Brewer, E. M. Whitley et al., “Canine digital
tumors: a veterinary cooperative oncology group retrospective
study of 64 dogs,” Journal of Veterinary Internal Medicine, vol.
19, no. 5, pp. 720–724, 2005.
[218] B. K. Wobeser, B. A. Kidney, B. E. Powers et al., “Diagnoses and
clinical outcomes associated with surgically amputated canine
digits submitted to multiple veterinary diagnostic laboratories,”
Veterinary Pathology, vol. 44, no. 3, pp. 355–361, 2007.
[219] M. Paradis, D. W. Scott, and L. Breton, “Squamous cell
carcinoma of the nail bed in three related giant schnauzers,”
Veterinary Record, vol. 125, no. 12, pp. 322–324, 1989.
[220] D. W. Knapp, N. W. Glickman, D. B. Denicola, P. L. Bonney,
T. L. Lin, and L. T. Glickman, “Naturally-occurring canine
transitional cell carcinoma of the urinary bladder: a relevant
model of human invasive bladder cancer,” Urologic Oncology,
vol. 5, no. 2, pp. 47–59, 2000.
[221] A. M. Norris, E. J. Laing, V. E. Valli et al., “Canine blad-
der and urethral tumors: a retrospective study of 115 cases
(1980–1985),” Journal of Veterinary InternalMedicine, vol. 6, no.
3, pp. 145–153, 1992.
[222] E. Teske, E. C. Naan, E. M. Van Dijk, E. Van Garderen, and
J. A. Schalken, “Canine prostate carcinoma: epidemiological
evidence of an increased risk in castrated dogs,”Molecular and
Cellular Endocrinology, vol. 197, no. 1-2, pp. 251–255, 2002.
[223] J. M. Snyder, F. S. Shofer, T. J. Van Winkle, and C. Mas-
sicotte, “Canine intracranial primary neoplasia: 173 Cases
(1986–2003),” Journal of Veterinary Internal Medicine, vol. 20,
no. 3, pp. 669–675, 2006.
[224] A. T. Liao, M. McMahon, and C. A. London, “Identi�cation of
a novel germline MET mutation in dogs,” Animal Genetics, vol.
37, no. 3, pp. 248–252, 2006.
[225] T. L. D. R. Nakagawa, H. Sakai, T. Yanai et al., “Simultaneous
aortic body tumor and pulmonary histiocytic sarcoma in a Flat-
coated Retriever,” Journal of Veterinary Medical Science, vol. 71,
no. 9, pp. 1221–1223, 2009.
[226] R. B. Rebhun and D. H. amm, “Multiple distinct malignan-
cies in dogs: 53 cases,” Journal of the American Animal Hospital
Association, vol. 46, no. 1, pp. 20–30, 2010.
[227] B. B. Takashima-Uebelhoer, L. G. Barber, S. E. Zagarins et
al., “Household chemical exposures and the risk of canine
malignant lymphoma, a model for human non-Hodgkin’s lym-
phoma,” Environmental Research, vol. 112, pp. 171–176, 2012.
[228] N. Rooney and D. Sargan, Pedigree dog breeding in the UK: a
major welfare concern?, http://www.rspca.org.uk/ImageLoca-
tor/LocateAsset?asset=document&assetId=1232712491490&
mode=prd.
[229] P. Bateson, Independent Inquiry into Dog Breeding, 2010,
http://breedinginquiry.�les.wordpress.com/2010/01/�nal-dog-
inquiry-120110.pdf.
[230] M. Sullivan, R. Lee, E. W. Fisher, A. S. Nash, and I. A.
McCandlish, “A study of 31 cases of gastric carcinoma in dogs,”
Veterinary Record, vol. 120, no. 4, pp. 79–83, 1987.
[231] K. L. Wucherer and V. Wilke, “yroid cancer in dogs: an
update based on 638 cases (1995–2005),” Journal of the Amer-
ican Animal Hospital Association, vol. 46, no. 4, pp. 249–254,
2010.
[232] H. M. Hayes Jr., G. P. Wilson, and H. F. Fraumeni Jr.,
“Carcinoma of the nasal cavity and paranasal sinuses in dogs:
descriptive epidemiology,”eCornell Veterinarian, vol. 72, no.
2, pp. 168–179, 1982.
[233] H. M. Hayes and B. Sass, “Chemoreceptor neoplasia: a study
of the epidemiological features of 357 canine cases,” Journal of
Veterinary Medicine, vol. 35, no. 6, pp. 401–408, 1988.
[234] A. Nødtvedt, H. Gamlem, G. Gunnes, T. Grotmol, A. Indrebø,
and L. Moe, “Breed diﬀerences in the proportional morbidity
of testicular tumours and distribution of histopathologic types
in a population-based canine cancer registry,” Veterinary and
Comparative Oncology, vol. 9, no. 1, pp. 45–54, 2011.
